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 Substrates of a ubiquitin-
dependent proteolytic system called the 
N-end rule pathway include proteins with 
destabilizing N-terminal residues.  N-
recognins, the pathway’s ubiquitin ligases, 
contain three substrate-binding sites.  The 
type-1 site is specific for basic N-terminal 
residues (Arg, Lys, His).  The type-2 site is 
specific for bulky hydrophobic N-terminal 
residues (Trp, Phe, Tyr, Leu, Ile).  We 
show here that the type-1/2 sites of UBR1, 
the sole N-recognin of the yeast 
Saccharomyces cerevisiae, are located in 
the first ~700 residues of the 1,950-residue 
UBR1.  These sites are distinct in that they 
can be selectively inactivated by 
mutations, identified through a genetic 
screen.  Mutations inactivating the type-1 
site are in the previously delineated 
~70-residue UBR motif characteristic of 
N-recognins.  Fluorescence polarization 
and surface plasmon resonance were used 
to determine that UBR1 binds, with Kd of 
~1 μM, to either type-1 or type-2 
destabilizing N-terminal residues of 
reporter peptides, but does not bind to a 
stabilizing N-terminal residue such as Gly.  
A third substrate-binding site of UBR1 
targets an internal degron of CUP9, a 
transcriptional repressor of peptide 
import.  We show that the previously 
demonstrated in vivo dependence of CUP9 
ubiquitylation on the binding of cognate 
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dipeptides to the type-1/2 sites of UBR1 
can be reconstituted in a completely 
defined in vitro system.  We also found 
that purified UBR1 and CUP9 interact 
nonspecifically, and that specific binding 
(which involves, in particular, the binding 
by cognate dipeptides to the UBR1’s type-
1/2 sites) can be restored either by a 
chaperone such as EF1A or through 
macromolecular crowding. 
 
 The N-end rule relates the in vivo half-
life of a protein to the identity of its N-terminal 
residue.  The ubiquitin (Ub)-dependent N-end 
rule pathway recognizes several kinds of 
degradation signals (degrons), including a set 
called N-degrons (Fig. 1A) (1-9).  Although 
prokaryotes lack the Ub system, they contain the 
N-end rule pathway, Ub-independent versions of 
it (10-18).  In eukaryotes, an N-degron consists 
of three determinants:  a destabilizing N-terminal 
residue of a protein substrate, an internal Lys 
residue(s) of the substrate (the site of formation 
of a poly-Ub chain), and a conformationally 
flexible region in the vicinity of these 
determinants (1,19-23).  The N-end rule has a 
hierarchic structure (Fig. 1A).  In eukaryotes, 
N-terminal Asn and Gln are tertiary destabilizing 
residues in that they function through their 
enzymatic deamidation, to yield the secondary 
destabilizing N-terminal residues Asp and Glu 
(24,25).  The destabilizing activity of N-terminal 
Asp and Glu requires their conjugation to Arg, 
one of the primary destabilizing residues, by Arg-
tRNA-protein transferase (arginyl-transferase or 
R-transferase) (5-7,26,27).  In mammals and 
other eukaryotes that produce nitric oxide (NO), 
the set of arginylated residues contains not only 
Asp and Glu but also N-terminal Cys (28), which 
is arginylated after its oxidation to Cys-sulfinate 
or Cys-sulfonate (27).  The in vivo oxidation of 
N-terminal Cys requires NO, as well as oxygen 
(O2) or its derivatives (Fig. 1A) (6,7,29).  The N-
end rule pathway is thus a sensor of NO, through 
the ability of this pathway to destroy proteins 
with N-terminal Cys, at rates controlled by NO, 
and by oxygen as well. 
 E3 Ub ligases of the N-end rule pathway, 
called N-recognins (1,8,29-37), recognize (bind 
to) primary destabilizing N-terminal residues, 
including Arg (Fig. 1A).  (The term “Ub ligase” 
denotes either an E2-E3 holoenzyme or its E3 
component.)  At least four N-recognins, 
including UBR1, mediate the N-end rule pathway 
in mammals (30-33,36).  The known N-recognins 
share a ~70-residue motif called the UBR box.  
Mouse UBR1 and UBR2 are sequelogous 
(similar in sequence) 200-kDa RING-type E3 Ub 
ligases that are 47% identical.  Several other 
UBR-containing N-recognins, either confirmed 
or putative ones, are HECT-type or SCF-type E3 
Ub ligases that share the UBR motif with the 
RING-type UBR1/UBR2 but are largely 
nonsequelogous to them otherwise (29-33).  
[“Sequelog” and “spalog” denote, respectively, a 
sequence that is similar, to a specified extent, to 
another sequence, and a 3D structure that is 
similar, to a specified extent, to another 3D 
structure (38).  The rigor-conferring advantage of 
“sequelog” and “spalog” is their evolutionary 
neutrality, in contrast to interpretation-laden 
terms such as “homolog”, “ortholog” and 
“paralog”.  The latter terms are compatible with 
the sequelog/spalog terminology and can be used 
to convey understanding about functions and 
common descent, if this (additional) information 
is available (38).] 
The N-end rule pathway of S. cerevisiae 
is mediated by a single N-recognin, UBR1, a 
225-kDa sequelog of mammalian UBR1 and 
UBR2 (Fig. 1A, C) (8,9).  S. cerevisiae UBR1 
(Fig. 1C) contains at least three substrate-binding 
sites.  The type-1 site is specific for basic 
N-terminal residues of protein substrates (Arg, 
Lys, His), while the type-2 site is specific for 
bulky hydrophobic N-terminal residues (Trp, 
Phe, Tyr, Leu, Ile).  The third binding site of 
UBR1 targets proteins through their internal 
(non-N-terminal) degrons, and is allosterically 
“activated” through a conformational change that 
is caused by the binding of short peptides to the 
UBR1’s other two binding sites, type-1 and type-
2.  The known substrate of the third binding site 
of UBR1 is CUP9 (8,39,40), a transcriptional 
repressor whose regulon includes PTR2 (41), a 
gene encoding transporter of di- and tripeptides.  
The reversal of UBR1 autoinhibition by 
(initially) imported peptides accelerates the 
UBR1-dependent ubiquitylation of CUP9, results 
in its faster degradation by the N-end rule 
pathway, and thereby causes derepression of 
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PTR2 and increased levels of the PTR2 
transporter.  This positive-feedback circuit allows 
S. cerevisiae to detect the presence of 
extracellular peptides and to react by increasing 
their uptake (8,40).  ClpS, a 12-kDa prokaryotic 
N-recognin, is an “adaptor” protein that mediates 
the (Ub-independent) targeting of N-end rule 
substrates in bacteria (13-15). ClpS recognizes 
type-2 (bulky hydrophobic) N-terminal residues, 
and contains a region of sequelogy to the 225 
kDa yeast UBR1, near its UBR box (2,13,42).  
This similarity and other common features of 
eukaryotic and prokaryotic N-end rule pathways 
(1,2,29) suggest that at least some N-degrons, N-
recognins and relevant “downstream” proteases 
had evolved before the split between eukaryotes 
and prokaryotes. 
 The functions of the N-end rule pathway 
include (i) the sensing of heme, owing to 
inhibition of the pathway’s ATE1 R-transferase 
(in both yeast and mammals) by hemin 
(Fe3+-heme), which also inhibits N-recognins, the 
latter at least in yeast (4) (Fig. 1A);  (ii) the 
sensing of NO and oxygen, and the resulting 
control of signaling by transmembrane receptors, 
through the conditional, NO/O2-mediated 
degradation of G-protein regulators RGS4, RGS5 
and RGS16 (6,7);  (iii) regulation of import of 
short peptides, through the degradation, 
modulated by peptides, of CUP9, the import’s 
repressor (8,40);  (iv) fidelity of chromosome 
segregation, through degradation of a separase-
produced cohesin fragment (43);  (v) regulation 
of apoptosis, through degradation of a caspase-
processed inhibitor of apoptosis (44,45);  (vi) a 
multitude of processes mediated by the 
transcription factor c-FOS, a conditional 
substrate of the N-end rule pathway (46);  (vii) 
regulation of the human immunodeficiency virus 
(HIV) replication cycle, through degradation of 
HIV integrase (47);  (viii) regulation of meiosis, 
spermatogenesis, neurogenesis and 
cardiovascular development in mammals 
(6,7,27,31,33), and the leaf senescence in plants 
(48).  Mutations in human UBR1 (Fig. 1A) 
(29,32,33) are the cause of Johansson-Blizzard 
Syndrome (JBS), which comprises mental 
retardation, physical malformations, and severe 
pancreatitis (49).  The abnormalities of UBR1-/- 
mice (30) include pancreatic insufficiency (49), a 
less severe counterpart of this defect in human 
JBS (UBR1-/-) patients. 
 In the present work, we used a genetic 
screen to probe the type-1 and type-2 substrate-
binding sites of S. cerevisiae UBR1.  This 
analysis demonstrated a modular organization of 
these sites, which could be selectively inactivated 
by specific mutations.  We also characterized 
physical interactions between UBR1 and CUP9 
that involve the internal (non-N-terminal) degron 
of CUP9, and employed a completely defined in 
vitro system to probe the conditional (modulated 
by dipeptides) polyubiquitylation of CUP9 by the 
UBR1-RAD6 Ub ligase.  In addition, we used 
both fluorescence polarization (FP) and surface 
plasmon resonance (SPR) to determine the 
affinities of purified UBR1 for specific N-
terminal residues of model peptides.  The results 
indicated, among other things, that at least the 
bulk of the observed in vivo specificity of UBR1 
for N-end rule substrates (1,2,29) (Fig. 1A, C) 
stems from differences in the physical affinity of 
UBR1 for destabilizing versus stabilizing 
N-terminal residues in the N-end rule. 
 
EXPERIMENTAL PROCEDURES 
 Yeast Strains, Media and Genetic 
Techniques – Synthetic yeast media (50) 
contained 0.67% yeast nitrogen base without 
amino acids (Difco) and either 2% glucose (SD 
medium) or 2% galactose (SG medium).  
Synthetic media lacking appropriate nutrients 
were used to select for (and maintain) specific 
plasmids.  Cells were also grown in rich medium 
(YPD) (51).  The S. cerevisiae strains were 
YPH500 (MATα ura3-52 lys2-801 ade2-101 
his3-Δ200 trp1-Δ63 his3-Δ200 leu2-Δ1), JD52 
(MATa trp1-Δ63 ura3-52 his3-Δ200 leu2-3,112 
lys2-801), JD55 (MATa ubr1Δ::HIS3 trp1-Δ63 
ura3-52 his3-Δ200 leu2-3,112 lys2-801) (52) 
SC295 (MATa, GAL4 GAL80 ura3‐52, leu2‐
3,112 reg1‐501 gal1 pep4‐3) (8) and PJ69-4A 
(MATa trp1-901 leu2-3,112 ura3-52 his3-200 
gal4Δ gal80Δ GAL2-ADE2 LYS2::GAL1-HIS3 
met2::GAL7-lacZ).  The medium for dipeptide 
import assays was methionine-lacking SD 
containing allantoin (1 mg/ml) and the toxic 
dipeptide L-leucyl-L-ethionine (Leu-Eth;  
37 μM) (39).  To induce the PCUP1 promoter, 
CuSO4 was added to a final concentration of 0.1 
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mM (52).  The XGal colony overlay assay was 
performed using 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (XGal) at 0.1 mg/ml, as 
described (53).  Transformation of S. cerevisiae 
was carried out using the lithium acetate method 
(50). 
Reporter Plasmids – Five sets of reporter 
plasmids were used.  Details of their construction 
are available upon request.  pUB23-X high copy 
plasmids expressed Ub-X-eK-β-galactosidase 
fusions (denoted below as Ub-X-βgal) from the 
galactose-inducible PGAL1 promoter (19,54).  
pBAX plasmids expressed Ub-X-eK-ha-URA3 
fusions (X=Arg, Leu), denoted below as Ub-X-
URA3.  The largely cotranslational 
deubiquitylation of these Ub fusions (55) yielded 
the corresponding X-βgal and X-URA3 reporter 
proteins. pBAX plasmids were constructed from 
pBAM, a pRS314-based low copy plasmid 
expressing Ub-Met-eK-ha-URA3 (tagged with 
the ha epitope (50)) from the PCUP1 promoter 
(56).  The term eK (extension (e) bearing lysines 
(K)) denotes a ~40-residue, E. coli Lac repressor-
derived sequence (21,54,56).  pDSRULB was 
constructed by subcloning the 5.4-kb ScaI 
fragment from pUB23-L (encoding Ub-Leu-βgal) 
into the SmaI site of pBAR, encoding Ub-Arg-
URA3.  The resulting low copy, TRP1-marked 
pRS314 plasmid expressed Ub-Arg-URA3 from 
the PCUP1 promoter and Ub-Leu-βgal from the 
PGAL1 promoter.  The similarly constructed 
pDSLURB expressed Ub-Leu-URA3 and Ub-
Arg-βgal.  The UPR (Ub/protein/reference) 
plasmids (21,40,57) for expression in 
S. cerevisiae, termed pBAXUPR, were based on 
the low copy pRS314 vector (58), and were 
constructed using PCR.  A pBAXUPR plasmid 
expressed DHFRha-UbR48-X-eK-ha-URA3 
(denoted below as DHFR-Ub-X-URA3) from the 
PCUP1 promoter (X=Met, Arg, Leu, Glu, Lys, His, 
Ile, Phe, Tyr, Trp).  The analogous UPR-based 
plasmids, termed pXβgalUPR, expressed 
DHFRha-UbR48-X-eK-βgal (X=Met, Arg, Leu), 
denoted as DHFR-Ub-X-βgal.  pXβgalUPR were 
constructed by cutting an appropriate pBAXUPR 
plasmid with BamHI and SmaI, recovering the 
vector-containing fragment, and ligating it to the 
3.8 kb βgal-encoding fragment produced from 
pUB23-M using BamHI and ScaI. 
UBR1 Plasmids – S. cerevisiae UBR1 
plasmids encoding wild-type or mutated UBR1 
included pRBUBR1, pRB208, pFlagUBR1, 
pFlagNT1UBR1, pUBR1NT1140Flag, 
p209NTUBR1Flag, p454NTUBR1Flag, 
p710NTUBR1Flag, p866NTUBR1Flag, and 
p1002NTUBR1Flag.  Details of construction are 
available upon request.  UBR1 alleles were 
expressed from the PADH1 promoter of the high 
copy, LEU2-marked YEplac181 vector (59), in 
SC295, a protease-deficient S. cerevisiae strain.  
UBR1 and its derivatives that were encoded by 
the above plasmids carried either the ha epitope 
(pRBUBR1 and pRB208) or the flag epitope.  
pRB208 and pRBUBR1 (a derivative of pRB208) 
encoded full-length, C-terminally ha-tagged S. 
cerevisiae UBR1 (UBR1ha).  pFlagUBR1 
encoded fUBR1, the N-terminally flag-tagged 
full-length UBR1.  pFlagNT1UBR1 encoded 
fUBR11-717, the N-terminally flag-tagged C-
terminally truncated variants of UBR1.  The 
design and expression of fUBR1 and fUBR11-717 
were described (8).  The plasmids 
p209NTUBR1Flag, p454NTUBR1Flag, 
p710NTUBR1Flag, p866NTUBR1Flag, and 
p1002NTUBR1Flag, which encoded, 
respectively, UBR1209-1140f, UBR1454-1140f, 
UBR1710-1140f, UBR1866-1140f, and UBR11002-1140f, 
were derivatives of pUBR1NT1140Flag (8), a 
high copy plasmid that expressed C-terminally 
flag-tagged UBR11-1140f from the yeast PADH1 
promoter.  The flag tag was located at the C-
terminus of the UBR1 derivatives except for the 
full-length fUBR1 and fUBR11-717.  UBR1 test 
proteins remained intact in yeast extracts that 
were prepared and incubated as previously 
described (8). 
 Expression and Purification of X-SCC1-
GST – A set of 3 pTYB12-X-SCC1-GST 
plasmids, which expressed Intein-CBD-X-SCC1-
GST fusions (X=Arg, Leu or Met), was 
employed for glutathione-S-transferase (GST)-
pulldown assays.  Details of construction are 
available upon request.  A specific pTYB12-X-
SCC1-GST plasmid was cotransformed into 
E. coli BL21(DE3) together with pRI952, which 
expressed tRNAs for the codons AGG, AGA and 
AUA that are rare in E. coli (60).  A fresh E. coli 
colony was inoculated into LB medium (600 ml) 
containing ampicilin (0.1 mg/ml) and 
chloramphenicol (25 μg/ml), followed by growth 
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at 37°C until OD600 of 0.5-0.8.  Isopropyl-β-D-
thiogalactopyranoside (IPTG) was then added to 
the final concentration of 0.4 mM, followed by a 
10-hr incubation, with shaking, at 18°C.  The 
cells were centrifuged at 5,000g for 10 min at 
4°C, washed once with phosphate-buffered saline 
(PBS), and frozen in liquid N2.  For isolation of 
proteins, the cell pellet was thawed at 0°C, then 
resuspended  in lysis buffer (0.1% Triton X-100, 
0.5 M NaCl, 20 mM Tris-HCl, pH 8.5) 
containing protease inhibitor cocktail (Roche, 
Indianapolis, IN) (6 ml of buffer per 1 g of 
pellet), and cells were disrupted by sonication on 
ice.  The suspension was centrifuged at 13,000g 
for 30 min.  The supernatant was loaded onto a 
pre-equilibrated chitin column (10-ml bed 
volume), at a rate not higher than 0.5 ml/min, and 
washed with 200 ml of column buffer (0.5 M 
NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8.5), 
at 1 ml/min.  The column was then flushed 
quickly with 30 ml of freshly prepared cleavage 
buffer (column buffer containing 40 mM 
dithiothreitol (DTT)), the flow was stopped, and 
the column was incubated at 23°C for 16 hr.  
X-SCC1-GST proteins were eluted with 30 ml of 
column buffer, concentrated with Centriplus 
(Millipore, Billerica, MA), and dialyzed against 
column buffer at 4°C.  The resulting samples 
were stored in small aliquots at -80°C.  The 
presence of desired N-terminal residues in the 
purified X-SCC1-GST proteins was verified 
using N-terminal sequencing by Edman 
degradation.  GST-CUP9 was expressed and 
purified as described (8). 
 Expression and Purification of  fUBR1 
and UBR11-1140f – To express and purify the C-
terminally flag-tagged UBR11-1140f, S. cerevisiae 
(SC295) carrying pUBR1NT1140Flag was 
grown to OD600 of ~1.5, and the cells were 
harvested by centrifugation.  The lysate was 
prepared as described (8), using lysis buffer 
(10 % glycerol, 0.05% NP40, 0.2 M KCl, 50 mM 
HEPES, pH 7.1), followed by the addition of 
anti-flag beads (Sigma, St. Louis, MO), 1-hr 
incubation with rocking, washing of the beads 
with lysis buffer, and the elution of UBR11-1140f 
with the flag peptide at 0.2 mg/ml in lysis buffer 
lacking NP40.  The expression and purification 
of N-terminally flag-tagged full-length UBR1 
(fUBR1) was similar to that of UBR11-1140f, with 
modifications.  A single colony of SC295 S. 
cerevisiae transformed with the pNTFlagUBR1 
was inoculated into 20 ml of yeast SD medium, 
and grown at 30°C to A600 of ~1.  The 20-ml 
culture was re-inoculated into 2 l of SD medium 
and grown to A600 of ~1, followed by the addition 
of equal volume of yeast YPD medium.  The 
cells were grown for ~3 more generations, until 
A600 of ~4, harvested by centrifugation, washed 
once with cold 1xPBS, and frozen in liquid N2.  
Other procedures, including purification, were 
identical to those with UBR11-1140f.  
Concentrations of purified fUBR1 and UBR11-
1140f were determined using the Protein Assay 
reagent (Bio-Rad, Hercules, CA).  Samples of 
purified fUBR1 and UBR11-1140f were frozen in 
liquid N2 and stored at -80°C. 
 GST-Pulldown Assays – An SCC1-based 
GST-fusion protein (~2 μg) (see above) was 
diluted to 0.3 ml in 1XPBS buffer (10% glycerol, 
1% Triton X-100, 137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4), 
and incubated with 20 μl of glutathione-
Sepharose-4B beads (Amersham Pharmacia 
Biotech) for 30 min at 4°C.  The beads were 
washed once with 0.5 ml of the 1XPBS buffer 
and twice with 0.5 ml of binding buffer (10% 
glycerol, 0.05% Nonidet-P40 (NP40), 0.2 M 
KCl, 50 mM HEPES, pH 7.5).  The washed 
beads, in 0.15 ml of the binding buffer, were 
incubated at 4°C for 1 hr with 0.1 ml of S. 
cerevisiae extract (~5 mg/ml total protein) 
containing either fUBR1 (N-terminally flag-
tagged UBR1) or its truncated derivatives (see 
above) at the same concentration.  These assays 
were performed in either the presence or absence 
of specific amino acids or amino acid derivatives, 
including dipeptides (Sigma), at concentrations 
indicated in figure legends.  Binding assays also 
contained ovalbumin (Sigma;  at 0.1 mg/ml, 
unless not stated otherwise), protease inhibitor 
cocktail (Sigma), and 50 μM bestatin (Sigma).  
The beads were washed twice with 0.2 ml of the 
binding buffer either containing or lacking 
specific dipeptides, depending on whether a 
binding assay contained them.  Washed beads 
were resuspended in 30 μl of SDS-PAGE loading 
buffer, heated at 95°C for 4 min, and 15-μl 
samples were subjected to SDS-10% PAGE, 
followed by immunoblotting with anti-flag M2 
antibody (Sigma). 
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 6
 CUP9-based GST-pulldown assays with 
fUBR1 were carried out similarly except for the 
following:  the total volume was 0.26 ml, with 1 
μl of purified fUBR1 (0.4 mg/ml), either in 
binding buffer (10% glycerol, 0.05% NP40, 50 
mM NaCl, 50 mM HEPES, pH 7.5), or in 
binding buffer supplemented with 60 μl of S. 
cerevisiae “empty” extract (no flag-tagged 
UBR1), or in GST-binding buffer containing 
ovalbumin (at 10 mg/ml);  or in 0.2 ml of binding 
buffer supplemented with 60 μl of S. cerevisiae 
extract containing fUBR1.  With UBR11-1140f, the 
assay was performed similarly, except that the 
reaction volume was 0.23 ml (0.2 ml of binding 
buffer plus 30 μl of extract from S. cerevisiae 
that produced UBR11-1140f or, alternatively, the 
same (30 μl) volume but containing 1 μl of 
purified UBR11-1140f (at 0.2 mg/ml), and 
ovalbumin at 50 mg/ml, as described in figure 
legends. 
 X-Peptide Pulldown Assays – Procedures 
were similar to those previously described 
(8,29,31,32).  Residues 2-9 of synthetic 12-mer 
X-peptides (X-Ile-Phe-Ser-Thr-Asp-Thr-Gly-
Pro-Gly-Gly-Cys, where X=Arg, Phe or Gly), 
were derived from residues 2-9 of Sindbis virus 
polymerase nsP4, a previously identified N-end 
rule substrate (1,61).  Hence the acronym for a 
specific X-peptide, “X-nsP4pep”.  20 μl (5 
mg/ml total protein) of S. cerevisiae extract 
containing (overexpressed) S. cerevisiae UBR1 
or its fragments (indicated above) was diluted 
into 0.2 ml of binding buffer (10% glycerol, 
0.05% NP40, 0.2 M KCl, 50 mM HEPES, pH 
7.5) in the presence of 0.1 mg/ml ovalbumin, 
protease inhibitor cocktail (Sigma) and 50 μM 
bestatin.  The samples were incubated with 5 μl 
(packed volume) of a carrier-linked X-nsP4pep 
for 1 hr at 4°C.  The beads were pelleted by a 
brief centrifugation, then washed with 0.3 ml of 
binding buffer three times.  The beads were then 
resuspended in 30 μl of SDS-PAGE sample 
buffer, and heated at 95°C for 4 min, followed by 
a brief centrifugation in a microcentrifuge, SDS-
10% PAGE of 3-μl samples of supernatants, and 
detection of flag-tagged UBR1 or its fragments 
by immunoblotting with anti-flag M2 antibody. 
 Labeling, Purification and Analysis of X-
Peptides – The above peptides were also 
employed as probes in the fluorescence 
polarization (FP) assay.  To conjugate Alexa 
Fluor-488-C5 maleimide (Invitrogen, Carlsbad, 
CA) to C-terminal Cys of an X-nsP4pep, this dye 
(0.6 μmole in 90 μl of dimethylsulfoxide 
(DMSO)) was added to 0.4 μmole of X-nsP4pep 
in 90 μl of DMSO, followed by incubation at 
room temperature for 4 hr.  Alexa-labeled X-
peptides were purified by HPLC, using 
analytical-scale VYDAC column (C18 reverse 
phase), followed by verification of purified 
peptides by mass spectrometry.  The 
concentration of labeled X-peptides was 
measured in using either BCA reagent (Pierce, 
Rockford, IL), or N-terminal sequencing by 
Edman degradation, or amino acid analysis, with 
similar results. 
 Fluorescence Polarization Assay – The 
concentration of fluorescently labeled X-peptides 
was kept at 10 nM.  Before carrying out the FP 
assay, we ascertained that the levels of 
background fluorescence of the binding buffer 
(10 % glycerol, 0.02% NP40, 0.2 M KCl, 50 mM 
HEPES, pH 7.1), of the competitor (unlabeled) 
dipeptides or X-peptides, and of the UBR11-1140f 
protein (in the same buffer), at their highest 
concentrations used, were low enough, less than 
5% of the fluorescence of a labeled X-nsP4pep in 
the assay.  The FP assay (62,63) was carried out 
as described in the published protocol 
(“Fluorescence Polarization:  Technical Resource 
Guide” (PanVera Corporation, now a part of 
Invitrogen)), with the following modifications.  
Purified fUBR11-1140 was serially diluted into ~14 
microcentrifuge tubes, covering the range of its 
concentrations from more than 10-fold below 
(estimated) dissociation constant (Kd) of UBR11-
1140f interactions with a cognate peptide to more 
than 10-fold above estimated Kd.  Identical 
samples of an Alexa-labeled X-nsP4pep were 
added to each of the above tubes, gently mixed, 
and incubated at 4°C for 30 min, in the final 
volume of 50 μl.  FP measurements were carried 
out using the Analyst AD&HT Assay Detection 
System (Molecular Devices, Sunnyvale, CA) and 
a xenon-arc lamp as a light source, in a standard 
FP configuration, with filter settings optimized 
for the excitation wavelength of 485 nm and the 
emission wavelength of 530 nm.  Two 
fluorescence measurements were collected for 
each well, with either parallel (S and S) or 
perpendicular (S and P) polarizers.  These data 
were used to calculate polarization, in 
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millipolarization units (mP), by the Analyst 
System.  The affinities, expressed as Kd’s, were 
calculated from the above data.  Their statistical 
significance was estimated by nonlinear 
regression analysis, using Prism (Graphpad, San 
Diego, CA).  FP-based competition assays were 
carried out similarly, except that concentration of 
UBR11-1140f was kept constant, and (unlabeled) 
competitor X-peptides were added to the binding 
assay.  The concentration of UBR11-1140f in 
competition FP assays was close to Kd (~1 μM;  
see Results) of the UBR11-1140f interaction with 
Arg-nsP4pep. 
 Surface Plasmon Resonance BIACORE 
Assay – The X-peptides Phe-nsP4pep, Arg-
nsP4pep or Gly-nsP4pep were linked, through 
their C-terminal Cys (see above), to biotin, using 
EZ-Link PEO-Iodoacetyl Biotin (Pierce), to 
allow immobilization of peptides onto 
streptavidin-coated SA sensor chips of 
BIACORE-2000 (Biacore).  Biotin-labeled X-
peptides were purified by HPLC, using 
analytical-scale VYDAC column (C18 reverse 
phase), followed by verification of purified 
peptides by MALDI-TOF.  The concentration of 
labeled X-peptides was measured using EZTM-
Biotin Quantification Kit (Pierce). A biotin-
containing X-peptide, at 0.1 μM in the running 
buffer (0.02% NP-40, 0.2 M KCl, 50 mM 
HEPES pH 7.5), was injected over the sensor 
chip surface at 10 μl min–1 at 25°C, resulting in 
X-peptide’s surface density of 30-35 resonance 
units.  Purified UBR11-1140f was serially diluted in 
running buffer and injected at 75 µl min–1 for 80 
sec at 25°C.  After 5 min, to allow dissociation of 
the formed complexes, the sensor chip was 
washed by two 1-min injections of 2 M MgCl2, at 
50 µl/min.  BIACORE readouts were corrected 
by subtracting readouts from the mock surface 
(lacking an X-peptide) as well as readouts from a 
buffer-only (control) injection.  Raw data were 
processed using Scrubber (BioLogic Software, 
Australia) and CLAMP programs and the 1:1 
Langmuir interaction model, with a correction for 
mass transport (64,65). 
UBR1-Dependent In Vitro Ubiquitylation 
System – This completely defined system, 
consisting exclusively of purified recombinant 
proteins and small compounds, was described in 
ref. (40), and in detail in ref. (66).  Briefly, C-
terminally His6-tagged S. cerevisiae UBA1 (E1, 
Ub-activating enzyme) was overexpressed in S. 
cerevisiae SC295 and purified using Ni-NTA 
(His6-affinity) chromatography, immobilized Ub 
(“covalent” affinity) chromatography and 
Superdex-200 gel filtration (67).  S. cerevisiae 
RAD6 (UBC2) was overexpressed in E. coli and 
purified by fractionation over DEAE, Mono-Q 
and Superdex-75 columns.  N-terminally flag-
tagged S. cerevisiae UBR1 (fUBR1) was 
overexpressed in S. cerevisiae as described in a 
section above, and was purified by fractionation 
over immobilized anti-flag M2 antibody, 
immobilized RAD6, and Superdex-200 columns 
(Fig. 7D).  N-terminally flag-tagged, C-
terminally His6-tagged S. cerevisiae fCUP9his6 
was expressed and labeled with 35S-methionine in 
E. coli, followed by purification over Ni-NTA 
and anti-flag M2 antibody columns.  Details of 
these and related procedures are described in ref. 
(66).  We also employed a similarly produced, 
labeled and purified pyCUP9his6, with a different 
N-terminal tag, called “polyoma” (py) that was 
bound by a monoclonal antibody (68) (AK6967;  
a gift from Dr. S. Stevens and Dr. J. Abelson 
(Caltech)).  The in vitro ubiquitylation reactions 
contained the following components:  7 µM Ub, 
50 nM UBA1, 50 nM RAD6, 50 nM UBR1, 550 
nM 35S-labeled fCUP9his6, 25 mM KCl, 5 mM 
MgCl2, 2 mM ATP, 0.1 mM dithiothreitol (DTT), 
25 mM HEPES (pH 7.5) and ovalbumin (as a 
carrier protein) at 0.5 mg/ml.  Pairs of dipeptides 
were added to final concentrations specified in 
the legend to Fig. 8.  All components except 
UBA1 were mixed on ice for 10 min;  UBA1 was 
then added and reactions shifted to 30°C.  The 
reactions were carried out for 10 min, and were 
terminated by adding an equal volume 2 x SDS-
PAGE loading buffer and heating at 95°C for 5 
min, followed by SDS-10% PAGE and 
autoradiography. 
Genetic Screen for Type-1 and Type-2 
UBR1 Mutants – Fig. 1B describes the screen’s 
design.  Reporter plasmids expressing either Arg-
URA3 (a type-1 N-end rule substrate) and Leu-
βgal (a type-2 N-end rule substrate) (pDSRULB 
plasmid), or Leu-URA3 (a type-2 substrate) and 
Arg-βgal (a type-1 substrate) (pDSLURB 
plasmid), were transformed into S. cerevisiae 
JD55, a ubr1∆ strain.  pRBUBR1, a high copy 
plasmid expressing UBR1 from the PADH1 
promoter, was mutagenized by treatment with 1 
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M hydroxylamine for 1 hr at 75°C.  DNA was 
precipitated with ethanol, redissolved in 1 mM 
EDTA, 10 mM Tris-HCl (pH 8.0), and 
hydroxylamine was removed using G25 spin-
desalting column (Roche).  Hydroxylamine-
treated pRBUBR1 was transformed into JD55 
(ubr1∆) carrying one of two reporter plasmids, 
either pDSRULB or pDSLURB.  The 
transformants were plated onto SD(-Ura) plates, 
and the resulting Ura+ colonies (cells that were, 
presumably, impaired in degrading either Arg-
URA3 or Leu-URA3) were replica-plated onto 
galactose-containing SG plates.  The colonies on 
SG plates were stained for βgal using XGal 
overlay.  Most of the colonies in these 
experiments stained blue.  Since the cells of these 
colonies were selected, in the preceding step, to 
be impaired in the degradation of one class (type-
1 or type-2) N-end rule substrates, the failure to 
degrade an X-βgal that belonged to the other class 
of N-end rule substrates (type-2 or type-1, 
respectively) meant that the corresponding alleles 
of UBR1 were defective in degrading both classes 
of N-end rule substrates  However, some white 
colonies on XGal were produced as well, with 
each of the two bi-reporter plasmids, pDSRULB 
and pDSLURB.  The corresponding pRBUBR1 
plasmids were rescued from these white colonies, 
and were retransformed into the JD55 (ubr1∆) 
cells carrying other reporter plasmids, either 
pBAM (Met-URA3), or pBAR (Arg-URA3), or 
pBAL (Leu-URA3).  The resulting transformants 
were plated onto either SD (+Ura) or SD(-Ura) to 
verify that the corresponding variants of UBR1 
were indeed selectively impaired in the 
degradation of either type-1 or type-2 N-end rule 
substrates. 
Mapping Type-1/2 Mutations in UBR1 – 
Five fragments of S. cerevisiae UBR1, from the 
pRB208 plasmid, were produced using the 
following restriction endonucleases:  fragment I, 
SmaI-SpeI (nt 1 to 510 of the UBR1 ORF);  
fragment II, SpeI-BglII (nt 510 to 1,653);  
fragment III, BglII-BalI (nt 1,653-3,511);  
fragment IV, BalI-XbaI (nt 3,511-4,515);  
fragment V, XbaI-PstI (nt 4,592-beyond the end 
of ORF).  Each of these fragments was replaced, 
in the non-mutant pRBUBR1, by the 
corresponding fragments from a rescued and 
amplified mutant pRB208, yielding five 
pRBUBR1-derived plasmids for every mutant 
plasmid.  The five plasmids were transformed, 
separately, into JD55 (ubr1∆) cells carrying either 
pBAR (Arg-URA3) or pBAL (Leu-URA3), and 
the transformants were tested for their ability to 
grow in the absence of uracil.  This way, we 
identified the regions of relevant alterations in the 
UBR1 ORF.  The corresponding fragments were 
then sequenced to identify the actual alteration(s). 
 Pulse-Chase Analysis – S. cerevisiae in 
liquid SD medium containing 0.1 mM CuSO4 
(A600 0.5-1) were labeled for 2 min at 30°C with 
0.15 mCi of 35S-methionine/cysteine (EXPRESS, 
New England Nuclear, Boston, MA) as described 
(21,52).  Cells were harvested by centrifugation, 
resuspended in 0.3 ml of SD medium containing 
10 mM L-methionine and 0.5 mg/ml 
cycloheximide, and incubated further at 30°C.  
Samples of 0.1 ml were removed during the 
incubation and added to microcentrifuge tubes 
containing 0.5 ml of 0.5-mm glass beads and 0.7 
ml of lysis buffer (1% Triton X-100, 0.15 M 
NaCl, 1 mM EDTA, 50 mM Na-HEPES (pH 7.5), 
and 1 x protease inhibitor cocktail (Sigma)).  The 
cells were lysed by vortexing with glass beads, 
followed by immunoprecipitation with anti-ha 
antibody (Covance, Princeton, NJ), SDS-PAGE, 
autoradiography, and quantitation (21],56).  
Immunoprecipitation of labeled CUP9-flag was 
carried out as described (39). 
β-Galactosidase and Other Assays – 
Cells in 5-ml cultures (A600 0.8-1) were pelleted 
by centrifugation at 12,000g for 2 min, lysed with 
glass beads in 20% glycerol, 1 mM dithiothreitol, 
0.1 M Tris-HCl (pH 8), and the activity of βgal 
was measured in the clarified extract using o-
nitrophenyl-β-D-galactoside, as described 
(50,69).  The activity was normalized to the total 
protein concentration, determined using Bradford 
assay (BioRad).  For growth-dilution assays, 
S. cerevisiae  strains were grown under selection 
for plasmids in SD medium to an A600 of 0.8-1.  
Cells (1.5 x 107) from each sample were pelleted 
by centrifugation and resuspended in 1 ml of 
water.  Four-fold serial dilutions of cell cultures 
were set up in microtiter plates as described (39), 
and cell suspensions were transferred to various 
media using a 48-pin applicator, followed by 
incubation at 30°C for ~36 hr to assay for growth. 
 
RESULTS 
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UBR1 Mutants That Are Selectively 
Defective in Targeting Type-1 or Type-2 N-End 
Rule Substrates – To locate the regions of S. 
cerevisiae UBR1 that encompass its type-1 and 
type-2 substrate-binding sites (see Introduction), 
and to determine whether these apparently 
distinct sites (1,28,69) are sufficiently modular 
(independent) to be selectively perturbed by 
mutations, we carried out a screen described in 
Fig. 1B and Experimental Procedures. A plasmid 
that expressed Arg-URA3 (a type-1 N-end rule 
substrate) and Leu-βgal (a type-2 N-end rule 
substrate), or an otherwise identical plasmid that 
expressed a “converse” set of reporters, 
Leu-URA3 (a type-2 substrate) and Arg-βgal (a 
type-1 substrate), were transformed into ubr1∆ 
S. cerevisiae, which lacked the N-end rule 
pathway.  pRBUBR1, a high-copy plasmid 
expressing UBR1, was mutagenized in vitro with 
hydroxylamine and transformed into ubr1∆ cells 
carrying one or the other of the double-reporter 
plasmids (Fig. 1B).  By replica-plating 
transformants on uracil-lacking SD plates, we 
could identify cells in which an X-URA3 reporter 
remained long-lived in the presence of pRBUBR1 
from the mutagenized pool, as those cells were 
Ura+, owing to higher steady-state levels of 
URA3.  (Both Arg-URA3 and Leu-URA3 were 
long-lived in ubr1∆ cells but short-lived in wild-
type cells (1,70).)  Ura+ colonies were then plated 
on galactose-containing SG plates.  The levels of 
galactose-induced Arg-βgal (in the Leu-URA3-
expressing plasmid) or Leu-βgal (in the Arg-
URA3-expressing plasmid) could then be 
assessed by staining the colonies with XGal.  A 
blue, i.e., high-βgal colony (which already proved 
to be Ura+ at the screen’s preceding step) would 
imply the presence of a UBR1 allele that was 
impaired in degradation of both type-1 and type-2 
substrates (Fig. 1B).  Most colonies in these 
experiments stained blue.  The rare white colonies 
on XGal suggested the presence of UBR1 
variants selectively impaired in one but not the 
other of two substrate-binding sites.  The 
pRBUBR1 plasmids were rescued from these 
colonies, and were retransformed into ubr1∆ cells 
carrying either Met-URA3 (not an N-end rule 
substrate, and a relatively long-lived protein), or 
Arg-URA3 (type-1 substrate), or Leu-URA3 
(type-2 substrate).  Plating transformants on 
either SD (+Ura) or SD(-Ura) plates could verify 
whether the corresponding variants of UBR1 
were selectively impaired in the degradation of 
type-1 or type-2 N-end rule substrates (Fig. 1B). 
 The initial screen involved ~2,000 
transformants bearing mutagenized UBR1.  With 
each of two reporter plasmids, ~10% of these 
transformants were Ura+.  Among these, no UBR1 
isolates were found that were unable to confer 
instability on a type-1 N-end rule substrate (basic 
N-terminal residues) but retained the activity 
against a type-2 substrate (hydrophobic N-
terminal residues). However, this screen did yield 
5 putative UBR1 variants of the opposite kind 
(active against type-1 but not type-2 N-end rule 
substrates).  A more extensive screen, with ~1 
x106 transformants, was then carried out 
exclusively for UBR1 variants of the former class 
(active against type-2 but not type-1 substrates).  
It yielded ~17,000 Ura+ colonies, i.e., isolates in 
which Arg-URA3 was at least partially stabilized.  
20 of these colonies showed low levels of βgal in 
the XGal assay (i.e., they retained degradation of 
Leu-βgal).  The pRBUBR1 plasmids encoding 
20 putative type-1-impaired and 5 putative type-
2-impaired UBR1 variants were rescued, and the 
specificity of their targeting defects was 
confirmed by re-testing them in ubr1∆ cells 
expressing either Arg-URA3 and Leu-βgal or 
Leu-URA3 and Arg-βgal, using, in particular, 
pulse-chase and immunoblot assays (data not 
shown;  see also below). 
 Identifying Mutations in UBR1 – The 
approximate locations of mutations within the 
5,850 bp UBR1 ORF were determined through 
fragment swapping between wild-type and mutant 
UBR1s, using unique restriction sites to divide 
UBR1 into five nonoverlapping fragments (see 
Experimental Procedures).  Once localized to a 
specific fragment, the actual mutation was 
determined by DNA sequencing.  All of the type-
1 and type-2 mutations were located in the N-
terminal 30% of UBR1.  Among ~20 type-1 
mutant isolates of UBR1 (those active with type-2 
substrates but inactive with type-1 substrates), 
only 5 different amino acid changes were present, 
with 18 of the 20 mutations affecting either Asp-
176 or Gly-172 (Fig. 1C).  All of recovered type-
1 mutations in UBR1 were missense alterations, 
one of them a double missense, in two adjacent 
residues.  Specific changes in the type-1 UBR1 
mutants, were (Cys-Val)145/146 → Tyr-Met (a 
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double missense;  one isolate);  Gly172 → Arg (7 
isolates);  Gly172 → Glu (4 isolates);  
Asp176 → Asn (5 isolates);  and Asp176 → Glu (2 
isolates), encompassing a ~30-residue region of 
UBR1 (positions 145-176) (Fig. 1C).  In contrast 
to type-1 UBR1 mutants, all 5 of the type-2 UBR1 
mutants contained different amino acid 
alterations;  collectively, these (type-2) alterations 
encompassed a different and larger region of 
UBR1 (positions 313-560).  Specific type-2 
alterations were Val313 → Ile;  Asp318 → Asn;  
His321 → Tyr;  Pro406 → Ser;  and Glu560 → Lys 
(Fig. 1C).  Together, the identified type-1 and 
type-2 mutations spanned a 416-residue stretch 
within the first 560 residues of the 1,950-residue 
UBR1 protein. 
Degradation of N-end Rule Substrates in 
Type-1 or Type-2 UBR1 Mutants – Specific type-
1 and type-2 S. cerevisiae UBR1 mutants were 
verified and further characterized by 
transforming the corresponding UBR1-expressing 
plasmids into JD55 (ubr1Δ) S. cerevisiae 
carrying pRβgalUPR or pLβgalUPR.  The latter 
are low-copy plasmids expressing, respectively, 
Arg-βgal or Leu-βgal reporter N-end rule 
substrates. The relative rates of in vivo 
degradation of X-βgals were assessed using 
extensively validated (9,24) steady-state 
measurements of βgal activity in whole cell 
extracts from ubr1Δ cells that carried plasmids 
expressing specific UBR1 mutants (Fig. 2A, B).  
The results confirmed the initial, screen-derived 
data that Arg-βgal was long-lived in the presence 
of type-1 UBR1 mutants, but was degraded with 
type-2 UBR1 mutants.  Conversely, Leu-βgal was 
long-lived in the presence of type-2 UBR1 
mutants, but short-lived with type-1 UBR1 
mutants (Fig. 2A, B).  In addition to steady-state 
levels of N-end rule substrates (Fig. 2A, B), their 
metabolic stability was also assessed by pulse-
chase analysis, using the Ub-protein-reference 
(UPR) technique (21,57).  This method provides 
a “built-in” (long-lived) reference protein as a 
part of reporter fusion, and thereby increases the 
accuracy of pulse-chase and analogous assays.  In 
agreement with steady-state data (Fig. 2A, B), 
Arg-URA3 was relatively long-lived in type-1 
UBR1 mutants, exemplified by UBR1D176E-1 cells 
(the suffixes “-1” or “-2” in the superscript 
denote the inactivation of, respectively, the type-
1 or type-2 substrate-binding sites of UBR1).  In 
contrast, Leu-URA3 was short-lived in a type-1 
mutant (Fig. 2D and data not shown;  see also 
Fig. 1C).  “Conversely”, Leu-URA3 was 
relatively long-lived in type-2 UBR1 mutants, 
exemplified by UBR1P406S-2, whereas Arg-URA3 
was short-lived in the same mutant (Fig. 2D and 
data not shown;  see also Fig. 1C).  (Both Arg-
URA3 and  Leu-URA3 were long-lived in the 
absence of UBR1 (Fig. 2C).) 
 UBR1-Dependent Targeting of CUP9 
Requires Intact Type-2 Binding Site of UBR1 – 
Previous work has shown that the N-end rule 
pathway controls the import of short peptides 
(8,39-41).  Specifically, a third substrate-binding 
site of S. cerevisiae UBR1, apparently distinct 
from its two other (type-1 and type-2) binding 
sites, targets CUP9.  The latter is a transcriptional 
repressor of, among other genes, PTR2, which 
encodes a plasma-membrane transporter that can 
import di- and tripeptides.  UBR1 targets CUP9 
for ubiquitylation and subsequent degradation 
through a distinct internal (non-N-terminal) 
degron of CUP9.  In wild-type cells, peptides 
with destabilizing N-terminal residues bind to the 
type-1 and type-2 binding sites of UBR1 and 
thereby allosterically activate its otherwise 
autoinhibited third site for binding to CUP9 
(8,40).  This reversal of autoinhibition leads to the 
targeting of CUP9 by UBR1, to accelerated 
degradation of CUP9, and thus to the induction of 
PTR2 expression and peptide import.  The 
resulting positive-feedback circuit allows 
S. cerevisiae to detect the presence of 
extracellular peptides and to react by increasing 
their uptake (8,40).  In ubr1Δ yeast, CUP9 is a 
relatively long-lived protein (t1/2 > 50 min).  As a 
result, the expression of PTR2 transporter is 
extinguished, making ubr1Δ cells incapable of 
importing peptides and therefore resistant to a 
toxic dipeptide such as leucyl-ethionine (Leu-Eth) 
(39). 
 We employed the toxic peptide resistance 
assay to probe in vivo aspects of UBR1 mutants 
identified in the present work.  Plasmids 
expressing type-1 or type-2 mutant alleles of 
UBR1 were transformed into ubr1Δ yeast, and the 
resulting transformants were streaked onto Leu-
Eth (toxic peptide) plates. Growth of cells on 
such plates indicates that the CUP9 repressor is 
metabolically stabilized in these cells, resulting in 
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a down-regulation of expression of PTR2 
transporter and therefore in hyperresistance of 
cells to Leu-Eth. The results  showed that CUP9 
was stabilized in cells transformed with all of 
type-2 UBR1 mutants (Fig. 3B), but was still 
degraded in cells transformed with four of the 
five type-1 UBR1 mutants (Fig. 3A).  (With the 
fifth type-1 mutant, UBR1CV145YM-1 (Fig. 1C), cell 
growth on Leu-Eth plates was partially retarded 
relative to ubr1Δ strains.)  These findings suggest 
that the third (CUP9-recognizing) site of UBR1 
either structurally overlaps with the type-2 
binding site or depends on this site for its 
function. 
 Specificity of UBR1 Interactions with N-
End Rule Substrates and X-Peptides – Our 
previous work described the use of N-recognin 
ligands containing the glutathione-S-transferase 
(GST) moiety linked to the C-terminus of a 
fragment of S. cerevisiae SCC1, a subunit of 
cohesin.  This 33-kDa SCC1 fragment, which 
normally bears N-terminal Arg, is produced in 
yeast through the conditional cleavage by 
separase ESP1, and is degraded by the N-end rule 
pathway (43).  Purified X-SCC1-GSTs (X=Arg, 
Leu, Met) bearing type-1 (Arg), or type-2 (Leu), 
or stabilizing (Met) N-terminal residues were 
linked to glutathione-Sepharose, and the 
previously characterized (8) GST-pulldown assay 
was carried out with yeast extracts that contained 
the overexpressed, flag-tagged, full-length fUBR1 
or its derivatives (Fig. 4).  Similarly to mouse 
UBR1 and UBR2 (31), S. cerevisiae fUBR1 did 
not bind to Met-SCC1-GST (Fig. 4D, lane 1) but 
bound to both Leu-SCC1-GST and Arg-SCC1-
GST (Fig. 4A, B, lanes 2).  This binding was 
specific for type-1 versus type-2 N-terminal 
residues, as the Arg-Ala and Leu-Ala dipeptides 
selectively inhibited the binding of corresponding 
(“alternative”) X-SCC-GST reporters (Fig. 4A, 
B).  To probe specificity of this inhibition, we 
tested other small compounds as well.  Whereas 
increasing concentrations of Arg-Ala inhibited 
the binding of Arg-SCC1-GST to fUBR1, neither 
Ala-Arg, nor an equimolar mixture of the 
corresponding free amino acids (Arg+Ala), nor 
Arg methyl ester (Arg-OMe), nor agmatine ((4-
aminobutyl)-guanidine), the decarboxylation 
product of Arg and a putative neurotransmitter 
(71)), exhibited this effect (Fig. 4A, C).  
Similarly, the binding of Leu-SCC1-GST to 
fUBR1 was inhibited by Leu-Ala but neither by 
Arg-Ala (31), nor by Ala-Leu, nor by Leu+Ala (a 
mixture of free amino acids) (Fig 4D). 
 In agreement with earlier findings (8), 
both full-length fUBR1 and UBR11-1140f (N-
terminal “half” of fUBR1) exhibited qualitatively 
indistinguishable patterns of binding specificity 
(Fig. 4E, F), indicating that UBR11-1140f contained 
the type-1 and type-2 binding sites.  It should be 
noted that while Arg-OMe (in contrast to Arg-
Ala) did not inhibit the binding of Arg-SCC1-
GST to either UBR11-1140f or full-length fUBR1, 
the analogous methyl ester Leu-OMe inhibited 
the binding of Leu-SCC1-GST apparently as 
efficaciously as did Leu-Ala (Fig. 4C-F).  Yet 
another difference between the inhibition patterns 
of type-1 and type-2 sites was a comparably 
strong inhibition, by either Leu-Ala or Leu-Asp, 
of the binding of Leu-SCC1-GST to UBR1 versus 
the absence of inhibition, by Arg-Asp (in contrast 
to Arg-Ala), of the binding of Arg-SCC1-GST to 
UBR1 (Fig. 4C-F).  Detailed understanding of 
these differences requires the knowledge of 
UBR1’s crystal structure. 
 The binding of UBR1 to destabilizing N-
terminal residues of polypeptides was also 
examined using the X-peptide assay, which 
employed a set of otherwise identical 12-mer 
peptides (termed X-nsP4pep) whose sequence X-
Ile-Phe-Ser-Thr-Asp-Thr-Gly-Pro-Gly-Gly-Cys 
(X=Arg or Phe) was derived, in part, from the N-
terminal sequence of nsP4, the RNA polymerase 
of the Sindbis virus and a physiological N-end 
rule substrate (27,61).  Purified X-nsP4pep 
peptides were crosslinked to microbeads through 
their C-terminal Cys residue (8,31,32).  Both full-
length fUBR1 and several of its truncated 
derivatives were overexpressed in S. cerevisiae 
and assayed for their binding to either Arg-
nsP4pep or Phe-X-nsP4pep.  Whereas UBR11-717f, 
the 717-residue N-terminal fragment of the 1,950-
residue UBR1, was capable of specific binding to 
X-nsP4pep peptides, shorter N-terminal 
fragments of UBR1 did not bind (Fig. 4G-H).  In 
addition, UBR1209-1140f, which differed from the 
binding-competent UBR11-1140f by deletion of the 
first 208 residues, did not bind to either Arg-
nsP4pep or Phe-X-nsP4pep (Fig. 4G, H and Fig. 
4J).  All of these findings were consistent with 
the conclusions from genetic mapping of the 
type-1 and type-2 sites (Fig. 1C). 
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 Measurements of Affinity Between UBR1 
and Peptide Reporters Using Fluorescence 
Polarization Assay – To measure the binding of 
UBR1 to different N-terminal residues of 
otherwise identical polypeptides we employed 
both fluorescence polarization (FP) (62,63,65) 
and surface plasmon resonance (SPR) (72,73).  
These measurements used purified UBR11-1140f 
(Fig. 4I).  Its specific binding to N-terminal 
residues of either protein-size substrates or short 
peptides was indistinguishable from that of full-
length fUBR1 in GST-pulldown assays (Fig. 4A-
F).  The otherwise identical Arg-nsP4pep, Phe-X-
nsP4pep, and Gly-nsP4pep peptides, with type-1 
destabilizing, type-2 destabilizing, and stabilizing 
N-terminal residues, respectively (Fig. 1A), were 
C-terminally conjugated to Alexa Fluor-488, 
followed by purification of the resulting 
fluorescent peptides by HPLC and verification of 
their structures by mass spectrometry (see 
Experimental Procedures). 
 The concentration of X-nsP4pep? (C-
terminal symbol denotes fluorescent tag) in FP 
assays was set at 10 nM, well below the 
(anticipated) micromolar-range of affinities 
between UBR1 and test peptides.  As expected 
(8), both Arg-nsP4pep? and Phe-nsP4pep? 
interacted with UBR11-1140f.  The calculated Kd’s 
(see Experimental Procedures) were ~1.0 µM and 
~0.7 µM, respectively.  In contrast, no binding to 
UBR11-1140f could be detected with the otherwise 
identical Gly-nsP4pep?, i.e., the corresponding 
Kd was at least 0.1 mM or higher (Fig. 5A, B).  
The affinities of X-nsP4pep peptides for 
UBR11-1140f were also measured in a competition 
FP assay, in which, for example, the binding of 
Phe-nsP4pep? to UBR11-1140f was titrated by the 
addition of Alexa-lacking (unlabeled) Phe-
nsP4pep (Fig. 5F).  The corresponding Kd was ~2 
µM, close to the value deduced from direct-
binding FP assay (Fig. 5B, F).  In contrast, the 
competition by unlabeled Arg-nsP4pep (a type-1 
destabilizing N-terminal residue) or by unlabeled 
Gly-nsP4pep (a stabilizing N-terminal residue) 
for the binding of Phe-nsP4pep? to UBR11-1140f 
was too weak to measure by FP (Fig. 5F).  The 
Kd of Arg-nsP4pep? binding to UBR11-1140f that 
was deduced from a similar competition assay, 
using unlabeled Arg-nsP4pep as a competitor, 
was ~1.2 µM, close to the value of ~1.0 µM from 
direct-binding assay (Fig. 5A, C).  Interestingly, 
however, the unlabeled Phe-nsP4pep could 
detectably compete with the binding of (labeled) 
Arg-nsP4pep? to UBR11-1140f (Fig. 5C), with the 
apparent Kd of ~11 µM, i.e., Phe-nsP4pep was a 
~10-fold weaker inhibitor of the binding of Arg-
nsP4pep? to UBR11-1140f than Arg-nsP4pep 
itself.  As to unlabeled Gly-nsP4pep, its apparent 
binding to the type-1 site of UBR11-1140f was 
weaker still but could still be detected in this 
competition assay, with the corresponding 
(apparent) Kd of ~36 µM (Fig. 5C). 
We conclude that the type-1 and type-2 
substrate-binding sites of UBR1 bind to the 
corresponding N-terminal residues of model 
substrates with approximately equal affinities 
(Kd’s of ~1 µM).  We also conclude that the 
UBR1’s type-2 site, which binds to bulky 
hydrophobic N-terminal residues (Fig. 1A), is 
significantly more discriminating than the type-1 
site.  Specifically, we could not detect the 
binding of noncognate N-terminal residues to the 
type-1 site of UBR1, in either qualitative or 
quantitative assays (Figs. 4 and 5B, F), whereas a 
type-2 N-terminal residue could weakly compete 
with a type-1 N-terminal residue for the binding 
to the type-1 site of UBR1, and a stabilizing N-
terminal residue could also compete, albeit even 
more weakly than a type-2 residue (Fig. 5A-F). 
We also carried out competition assays 
with unlabeled dipeptides and other dipeptide-
size compounds, versus either Arg-nsP4pep? or 
Phe-nsP4pep? (Fig. 5D, E, G).  Some of these 
competitors were also used in qualitative binding 
assays (Fig. 4D, E).  The results of FP-based 
competition assays indicated that dipeptides (as 
distinguished from 12-mer X-nsP4pep peptides) 
with cognate N-terminal residues were 
significantly (5-10-fold) weaker competitors 
relative to unlabeled cognate X-nsP4pep peptides 
(Fig. 5D, G), and that dipeptides (or analogous 
compounds) with noncognate N-terminal 
residues were either not competitors at all or 
much weaker competitors (see the legend to Fig. 
5D, G for details).  Among the tested dipeptide 
sequences, Ala at position 2 of an otherwise 
cognate dipeptide (Arg-X or Leu-X) resulted in 
best competitor dipeptides, whereas a negatively 
charged (Asp) residue at position 2 significantly 
decreased the affinity of a dipeptide for the 
corresponding (type-1 or type-2) substrate-
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binding site of UBR1 (Fig. 5D, G).  A basic (Arg 
or Lys) residue at position 2 was not as 
detrimental for the interaction of dipeptide with 
UBR1 (Fig. 5D, G). 
While the length of a competitor peptide 
is less important than whether or not it bears a 
cognate N-terminal residue, the data of Fig. 5H, I 
indicate that the length of a peptide (in the tested 
range) is a significant, apparently independent 
parameter that determines its affinity for UBR1.  
One possibility is that the peptide’s C-terminal 
carboxyl group (e.g., its negative charge) would 
weaken the binding of peptide to its cognate 
(type-1 or type-2) binding site of UBR1, unless 
the peptide is long enough to place its C-terminal 
carboxyl group away from the binding site.  This 
interpretation would also account for the fact that 
free “cognate” amino acids (in contrast to 
dipeptides bearing them as N-terminal residues) 
do not bind to UBR1 (Fig. 4C, E). 
 Measurements of Affinity Between UBR1 
and Model Peptides Using Surface Plasmon 
Resonance – To measure the affinity between 
UBR11-1140f and 12-mer X-nsP4pep peptides 
using a technique other than FP (Fig. 5), we 
employed surface plasmon resonance (SPR) and 
BIACORE-2000 (64,65,72,73).  Phe-nsP4pep, 
Arg-nsP4pep or Gly-nsP4pep, modified to bear a 
C-terminal biotin moiety (see Experimental 
Procedures) were immobilized on streptavidin 
coated sensor chips.  Purified UBR11-1140f (see 
Fig. 4I) was serially diluted in the running buffer 
and injected over the chip surface for 80 sec.  
BIACORE readouts were corrected by 
subtracting readouts from the mock surface 
(lacking an X-peptide) as well as readouts from 
buffer-only (control) injections.  Raw data were 
processed using Scrubber (BioLogic Software), 
and were globally fit using CLAMP (64), 
yielding the corresponding Kd’s.  As shown in 
Fig. 6, BIACORE detected the binding of 
UBR11-1140f to either Arg-nsP4pep (bearing a 
type-1 destabilizing N-terminal residue) or Phe-
nsP4pep (bearing a type-2 destabilizing N-
terminal residue), with the Kd’s of ~1.2 µM and 
~1.0 µM, respectively (Fig. 6), in excellent 
agreement with the results of FP-based 
measurements (Fig. 5 and preceding section).  In 
contrast, the otherwise identical Gly-nsP4pep, 
bearing a stabilizing N-terminal residue, did not 
exhibit a detectable binding to UBR11-1140f (Fig. 
6C).  These BIACORE-based findings (Fig. 6) 
demonstrated yet again (in addition to GST-
pulldown and FP-based data) that at least the 
bulk of the in vivo specificity of UBR1 for N-end 
rule substrates (Fig. 1A, B) (see Introduction) 
stems from differences in its physical affinity for 
destabilizing versus stabilizing N-terminal 
residues in the N-end rule. 
 Nonspecific Binding of Purified UBR1 to 
CUP9, and Restoration of Specificity Through 
Chaperones and Macromolecular Crowding – 
Through its type-1 and type-2 sites, the 225-kDa 
UBR1 can bind to primary destabilizing N-
terminal residues in proteins or short peptides 
apparently “nonconditionally”, i.e., under all 
conditions tested (8) (Figs. 4-6).  In contrast, 
UBR1 can bind, through its third binding site, to 
its physiological substrate CUP9 only if the 
type-1 and type-2 sites of UBR1 are occupied by 
cognate N-terminal residues of ligands such as 
dipeptides (8) (e.g., Fig. 7E-G, lanes 2, 3).  This 
dependence of the UBR1-CUP9 interaction (via 
the C-terminus-proximal degron of CUP9 (8) 
(Fig. 7B, C)) on the state of occupancy of 
UBR1’s other two binding sites yields, in vivo, a 
positive-feedback circuit through which S. 
cerevisiae can sense the presence of extracellular 
peptides and accelerate their uptake (8,40) (see 
Introduction).  The negligible binding of CUP9 
by UBR1 in the absence of occupancy of its 
type-1/2 sites (e.g., Fig. 7E-G, lanes 2, 3) is thus 
the consequence of a negligible fraction of UBR1 
molecules, under these conditions, that exhibit an 
“open” (active) CUP9-binding site. 
The binding of type-1/2 ligands to the 
corresponding sites of UBR1 increases, in an 
ensemble of UBR1 molecules, the probability of a 
conformational transition that “opens up” the 
CUP9-binding site of UBR1 (8).  The type-1/2 
sites of UBR1 encompass its N-terminus-
proximal UBR domain (Fig. 1C and 
Introduction).  The allosteric influence of UBR1-
bound dipeptides on the probability of transition 
that induces the UBR1-CUP9 interaction was 
shown to require the evolutionarily conserved C-
terminal region of UBR1 that includes two 
critical cysteines, Cys-1703, and Cys-1706 (8).  
In particular, UBR11-1140f, the N-terminal “half” of 
UBR1, retains all three of its substrate-binding 
sites but exhibits a constitutively “open” (active) 
CUP9-binding site.  More recent findings, using 
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UBR1 derivatives that contained sequences 
allowing site-specific cleavages of UBR1 
indicated that a conformational transition in 
UBR1 that “opens up” its CUP9-binding site is 
“subtle”, in that it does not appear to involve a 
large-scale repositioning of UBR1 domains3. 
 GST-pulldowns with UBR1 versus 
GST-CUP9 were carried out in the presence of 
yeast extract (8) (e.g., Fig. 7E-G, lanes 2, 3).  We 
repeated these assays with purified UBR1 (see 
Experimental Procedures) and GST-CUP9.  
Surprisingly, the specificity of UBR1-CUP9 
interaction, i.e., its dependence on the presence of 
dipeptides with destabilizing N-terminal residues, 
as well as its dependence on the presence of C-
terminal degron of CUP9 (66) were abolished 
with purified UBR1:  it bound to GST-CUP9 
irrespective of the presence or absence of 
dipeptides, and irrespective of the presence or 
absence of the UBR1-specific degron of CUP9 
(Fig. 7C, F, and data not shown).  These effects 
of using purified UBR1 (as distinguished from 
UBR1 in the presence of yeast extract) were also 
observed with its N-terminal fragment 
UBR11-1140f (Figs. 4K and 7B).  For example, in 
the presence of yeast extract, UBR11-1140f bound 
to CUP9 constitutively (i.e., independently of the 
presence of dipeptides) (8) but specifically (i.e., 
depending on the presence of CUP9’s degron) 
(Fig. 7B).  However, purified UBR11-1140f bound 
either to full-length CUP9 (containing its C-
terminal degron) or to C-terminally truncated 
CUP91-221 that lacked the degron(Fig. 4K, lanes 1-
6).  The same pattern was observed with purified 
full-length UBR1 versus CUP9L294P that contained 
a previously characterized degron-inactivating 
missense mutation (8) (Fig. 7I). 
We found that the specificity of these 
interactions, i.e., their dependence on the 
presence of CUP9’s degron, could be restored if 
GST-CUP9 pulldowns with purified UBR11-1140f 
or purified UBR1 were carried out in the presence 
of a “carrier” protein such as ovalbumin, at 
concentrations (10 to 50 mg/ml) that would be 
expected to produce “macromolecular crowding” 
(Fig. 4K, lanes 4-6, compare with lanes 7, 8;  Fig. 
7F, lanes 5, 6, compare with lanes 7, 8;  Fig. 7G, 
lanes 9, 10, compare with lanes 5, 6;  Fig. 7K, 
lanes 5, 6, compare with lanes 7, 8).  These terms 
refer to volume-exclusion and related effects that 
recapitulate, in part, the properties of intracellular 
milieu, where the total protein concentration can 
be as high as 200-400 mg/ml (74-76). 
As expected, and similarly to the effect of 
ovalbumin, the re-addition of fUBR1-lacking 
yeast extract to purified fUBR1 also restored the 
specificity of UBR1 binding to GST-CUP9 
(Fig. 7E).  We noticed that GST-CUP9 interacted 
not only with fUBR1 in the yeast extract but also 
with another protein that was present in extracts 
irrespective of the presence of fUBR1 (data not 
shown).  Mass spectrometry (MS) of that protein 
identified it as EF1A, which functions as a 
translation elongation factor, a protein chaperone, 
and is a highly abundant protein ((77) and refs. 
therein).  We employed two chromatographic 
steps, DEAE-Sepharose and CM-Sepharose 
chromatography, to purify S. cerevisiae EF1A to 
near homogeneity (Fig. 7H).  The addition of 
purified EF1A to GST-CUP9 pulldowns with 
purified fUBR1, at the EF1A concentration of 1.2 
mg/ml (a relatively low level, in comparison to 
minimally effective concentrations of ovalbumin) 
was found to restore the specificity of UBR1-
CUP9 interactions.  Specifically, in the presence 
of purified EF1A, a significant binding of purified 
fUBR1 to GST-CUP9 was observed only in the 
presence of dipeptides with destabilizing N-
terminal residues (Fig. 7G, lanes 7, 8;  compare 
with lanes 2-6 and 9, 10). 
A parsimonious interpretation of these 
findings with purified UBR1 versus its 
supplementation with ovalbumin, or with yeast 
extract, or with EF1A is that CUP9, a 
transcriptional repressor, functions in vivo as a 
complex containing “global” corepressors TUP1 
and SSN6 (78).  In the absence of these CUP9 
ligands, the CUP9 moiety in purified GST-CUP9 
may exhibit a “sticky” region(s) that mediates a 
nonspecific interaction between CUP9 and 
UBR1.  This region(s) of CUP9 may be shielded 
from UBR1 by interactions with either EF1A, 
acting as a chaperone, and/or with another 
chaperone-like proteins in the yeast extract, thus 
allowing a specific UBR1-CUP9 interaction to be 
detected.  Because “crowding” levels of 
ovalbumin (10-50 mg/ml) also restore the 
specificity of UBR1-CUP9 interaction (Fig.4K 
and Fig. 7F, G), the presumed “sticky” region(s) 
of CUP9 may be partially unfolded in the absence 
of EF1A or ovalbumin.  In vivo, CUP9 is likely to 
be targeted by UBR1 for ubiquitylation (and 
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subsequent degradation) as a part of the TUP1-
SSN6-CUP9 complex (79,80).  The previously 
discovered subunit selectivity of the N-end rule 
pathway (20,23) is expected to make possible 
selective degradation of the CUP9 moiety in the 
TUP1-SSN6-CUP9 complex in vivo, leaving the 
corepressor TUP1-SSN6 intact.  This model 
remains to be addressed experimentally. 
 Synergistic Effects of Type-1/2 Dipeptides 
in a UBR1-Dependent Ubiquitylation System – 
Our studies of the targeting of CUP9 by the 
UBR1 Ub ligase (8,40) included the development 
of an in vitro system that consisted exclusively of 
small compounds and purified recombinant 
proteins (Ub, UBA1, RAD6, UBR1, and CUP9) 
(see Experimental Procedures and ref. (66)).  This 
system exhibited the UBR1-dependent, RAD6-
dependent polyubiquitylation of CUP9 that was 
enhanced by single dipeptides such as Trp-Ala or 
Lys-Ala that bore destabilizing N-terminal 
residues, but was not enhanced by 
compositionally identical single dipeptides such 
as Ala-Trp or Ala-Lys, which bore a stabilizing 
N-terminal residue (40,66).  As with most such 
systems, the extent of its specificity, in this case 
the extent of its UBR1 dependence vis-à-vis 
polyubiquitylation of CUP9, was a function of 
both UBR1, RAD6 and Ub concentrations (ref. 
(66) and data not shown.)   
In the present study, we asked whether 
the system’s specificity could also recapitulate, at 
the level of UBR1-dependent polyubiqutylation 
of CUP9, the previously demonstrated 
dependence of the UBR1-CUP9 in vitro 
interaction (assayed by GST-pulldowns) on the 
presence of both type-1 and type-2 dipeptides 
(e.g., both Arg-Ala and Leu-Ala) (8) (see also 
Fig. 7).  Indeed, we observed a clear enhancement 
of the UBR1-dependent CUP9 polyubiquitylation 
upon the addition of both Arg-Ala and Leu-Ala 
(at micromolar levels), as distinguished from 
either Arg-Ala alone or Leu-Ala alone (Fig. 8).  
Specifically, little polyubiquitylated CUP9 was 
formed in reactions that contained no added 
dipeptides (Fig. 8, lane 2).  Some 
polyubiquitylated CUP9, bearing relatively short 
poly-Ub chains, was formed in the presence of a 
mixture of Leu-Ala (a type-2 dipeptide) and Ala-
Arg (bearing a stabilizing N-terminal residue), at 
2 µM each (Fig. 8, lane 5).  The distribution of 
poly-Ub chain sizes shifted slightly upward at 10 
µM of Leu-Ala plus Ala-Arg (Fig. 8, lane 6;  
compare with lanes 2, 5).  However, when a 
mixture of type-1 (Arg-Ala) and type-2 (Leu-Ala) 
dipeptides was present, the polyubiquitylation of 
CUP9 was detectable already at 0.8 µM of each 
dipeptide (Fig. 8, lane 7;  compare with lane 2).  
The average size of CUP9-linked poly-Ub chains  
greatly increased at 2 µM of type-1/2 dipeptides, 
and the average size of such chains was much 
higher than the one observed at the same 
concentration of Leu-Ala plus Ala-Arg (Fig. 8, 
lane 8;  compare with lane 6).  Finally, at 5 µM of 
type-1/2 dipeptides, the size of most poly-Ub 
chains became too large for the resulting CUP9 
conjugates to be fractionated under conditions 
used, resulting in a diffuse “band” of large 
conjugates near the origin of the gel (Fig. 8, lane 
9;  compare lanes 7, 8, and also with lane 6, 
which illustrates the average size of poly-Ub 
chains in the presence a type-2 dipeptide (Leu-
Ala plus Ala-Arg) at 10 µM, twice as high as the 
5 µM level of type-1/2 dipeptides together).  
Thus, in addition to the previously demonstrated 
dependence of the physical binding of UBR1 to 
CUP9 on the presence of both type-1 and type-2 
dipeptides (8) (see also Fig. 7), our present 
findings (Fig. 8) strongly suggest that the 
processivity of polyubiquitylation of CUP9 by the 
UBR1-RAD6 Ub ligase is increased when both of 
the type-1 and type-2 binding sites of UBR1 are 
occupied by cognate dipeptides.  One constraint 
on possible mechanisms of UBR1 processivity 
stems from the fact that the bulk of either purified 
UBR1 or UBR1 in yeast extracts is a monomer, 
as determined by gel filtration (refs. (66,70) and 
data not shown). 
 
DISCUSSION 
 Since the 1990 cloning of S. cerevisiae 
UBR1, the first molecularly characterized E3 Ub 
ligase (70), it was clear that at least the bulk of 
specificity of UBR1 toward polypeptides with 
primary destabilizing N-terminal residues 
(Fig. 1A) stems from its selective binding to those 
residues, rather than, e.g., from effects of a bound 
N-terminal residue of a substrate on the kinetics 
of substrate ubiquitylation by the UBR1-RAD6 
holoenzyme.  For example, immunoprecipitation 
of an epitope-tagged UBR1 from yeast extracts 
containing Arg-βgal (an N-end rule substrate) 
versus the otherwise identical Val-βgal (not an N-
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end rule substrate) coprecipitated Arg-βgal but 
not Val-βgal (70).  Quantitative measurements, in 
the present study, of these differential affinities of 
UBR1 confirmed and extended the earlier 
inferences.  Specifically, using both fluorescence 
polarization (FP) and surface plasmon resonance 
(SPR), we found that UBR1 bound to either 
type-1 (basic) or type-2 (bulky hydrophobic) N-
terminal residues of 12-mer X-peptides with Kd of 
~1 µM.  In contrast, neither FP nor SPR could 
detect the binding of UBR1 to an otherwise 
identical reporter peptide bearing a stabilizing N-
terminal residue such as Gly (Figs. 5 and 6). 
 The above affinity of the 225-kDa yeast 
UBR1 for cognate (primary destabilizing) N-
terminal residues (Fig. 1A) is in agreement with 
the approximately equal affinity of ClpS, the 
12 kDa E. coli N-recognin (see Introduction), for 
its cognate (bulky hydrophobic) N-terminal 
residues (2,13).  The relatively low (Kd of ~1 µM) 
affinity of UBR1 for N-degrons, i.e., the 
relatively high rate of UBR1 dissociation from 
substrate proteins may facilitate the transfer of a 
targeted, polyubiquitylated substrate to 
downstream components of the N-end rule 
pathway, such as Ub-binding chaperones and the 
26S proteasome.  Although UBR1 is a relatively 
scarce protein in S. cerevisiae (~300 molecules 
per haploid cell4), the UBR1-dependent N-end 
rule pathway is highly efficacious.  For example, 
wild-type levels of UBR1 sufficed to reduce the 
steady-state level of an N-end rule reporter such 
as Arg-βgal to less than 5% of its level in the 
absence of UBR1, even under conditions where 
Arg-βgal was expressed from the induced PGAL1 
promoter on a high copy plasmid and would have 
been an abundant protein in the absence of its 
degradation by the N-end rule pathway (9,54,69).  
UBR1 was also found to interact with specific 
subunits of the 26S proteasome (81), in apparent 
contradiction to the notion of rapid transfer of a 
UBR1-targeted substrate to “downstream” 
effectors.  One possibility is that a significant 
fraction of UBR1 molecules might be associated, 
at any given time, with the (much more abundant) 
26S proteasome.  In other words, the UBR1-
dependent targeting of N-end rule substrates may 
take place in the context of a UBR1-proteasome 
complex. This model remains to be addressed 
experimentally. 
 Genetic screens, in the present work, for 
UBR1 mutants that lost the ability to target type-1 
N-end rule substrates but retained the targeting of 
type-2 substrates and vice versa have yielded both 
classes of mutants, thereby indicating a modular 
organization of the type-1 and type-2 substrate-
binding sites of UBR1.  The type-1 site (it binds 
to N-terminal Arg, Lys or His) is located in the 
~70-residue UBR domain of UBR1, whereas the 
type-2 site (it binds to N-terminal Trp, Phe, Tyr, 
Leu, or Ile) resides at least in part downstream of 
the type-1 site and moreover, may partially 
overlap (or functionally interact) with the third 
substrate-binding site of UBR1, the one that 
targets CUP9 (Figs. 1C and 3).  We also found 
that the previously characterized UBR1-
dependent in vitro ubiquitylation system (40,66) 
exhibited a synergistic effect of two dipeptides 
with cognate type-1 and type-2 N-terminal 
residues on the rate of CUP9 polyubiquitylation 
(Fig. 8).  This ubiquitylation-based result 
extended our earlier observation (8) (see also Fig. 
7) that the physical binding of UBR1 to CUP9 in 
vitro required the occupancy of both type-1 and 
type-2 binding sites of UBR1 by added 
dipeptides. 
Another finding of the present work is 
that a specific (CUP9 degron-specific) in vitro 
interaction between GST-CUP9 and UBR1 
required the presence of either yeast extract, or 
the translation factor EF1A (which is known to 
function as a chaperone), or ovalbumin, the latter 
at concentrations that produce macromolecular 
crowding (Figs. 4 and 7).  As described in 
Results, this requirement is likely to stem from 
the fact that CUP9 functions in a complex with 
the general repressor TUP1-SSN6 (78-80).  Thus, 
in contrast to the in vitro setting of purified 
GST-CUP9 (Fig. 7), UBR1 may not have access, 
in vivo, to (potentially) UBR1-interacting surfaces 
of CUP9 outside of its C-terminus-proximal 
degron (8) (Fig. 7).  It remains to be determined 
whether the short in vivo half-life of CUP9 (~5 
min in the absence of UBR1-activating dipeptides 
in growth medium and < 2 min in their presence 
(40)) reflects the UBR1-mediated targeting of 
CUP9 directly at chromatin, i.e., at transcriptional 
promoters that comprise the CUP9 regulon. 
 In the S. cerevisiae UBR1 Ub ligase, in 
its mammalian sequelogs UBR1/UBR2, and in 
some other N-recognins of mammals and plants 
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(31,32,35)  the UBR domain contains at least the 
type-1 substrate binding site.  A UBR domain is 
also present in UBR1 sequelogs that do not 
function as N-recognins.  One example is the S. 
cerevisiae UBR2 Ub ligase, which is distinct 
from metazoan UBR2.  Physiological substrates 
of S. cerevisiae UBR2 include RPN4, a short-
lived transcription factor that regulates the 
synthesis of proteasomal subunits (82,83).  The 
mammalian UBR3 Ub ligase (its functions 
include regulation of olfaction) is yet another 
UBR domain-containing E3 that is not an N-
recognin (29).  Physiological ligands of the UBR 
domains in Ub ligases that are not N-recognins 
remain to be discovered. 
Although prokaryotes lack the Ub 
system, they contain the N-end rule pathway, Ub-
independent versions of it (10-15).  Remarkably, 
although the N-end rules of prokaryotes are 
subsets of eukaryotic N-end rules, the underlying 
mechanisms differ beyond the absence of Ub 
from prokaryotes.  For example, the N-end rule of 
Vibrio vulnificus, a human pathogen, is nearly 
identical to the mammalian N-end rule.  
Specifically, among the 13 destabilizing N-
terminal residues in the mammalian N-end rule 
(Fig. 1A), only His, Asn and Gln are stabilizing 
residues in V. vulnificus (12).  (N-terminal Asn 
and Gln are destabilizing in eukaryotes, owing to 
the presence of N-terminal amidases (Fig. 1A), 
which are absent from examined prokaryotes.)  
However, the similarity of eukaryotic and 
prokaryotic N-end rules is attained through 
distinct designs.  For example, the N-terminal 
Arg and Lys residues are destabilizing in 
eukaryotic N-end rules because they are 
recognized directly (together with His) by the 
type-1 substrate-binding sites of the pathway’s 
Ub ligases (see Introduction).  In contrast, N-
terminal Arg and Lys are secondary destabilizing 
residues in both E. coli and V. vulnificus, owing 
to the presence of L/FK,R-transferase, which 
conjugates Leu (or Phe) to N-terminal Arg or Lys 
(10,11,16-18).  The resulting additional (bulky 
hydrophobic) residue at the N-terminus of a 
substrate is recognized by the ClpS N-recognin, 
which mediates the delivery of bacterial N-end 
rule substrates to the proteasome-like ClpAP 
protease (13-15).  Furthermore, the N-terminal 
Asp, Glu and (oxidized) Cys residues in 
eukaryotes are arginylated (by R-transferase) 
before their recognition (through the conjugated 
N-terminal Arg) by Ub ligases (Fig. 1A).  In 
contrast, N-terminal Asp and Glu in prokaryotes 
are either stabilizing (unrecognized) residues, e. 
g., in E. coli, or are destabilizing (e. g., in V. 
vulnificus) but through their leucylation, i.e., the 
conjugation to Leu by the bpt-encoded LD,E-
transferase, whose specificity differs from that of 
the aat-encoded L/FK,R-transferase (2,12). 
Thus, the “addition” of Arg and Lys to an 
early (primordial) N-end rule (which presumably 
comprised a set of bulky hydrophobic residues) 
during the evolution of eukaryotes involved the 
emergence of an “extra”,  type-1 (Arg/Lys/His-
specific) binding site in Ub ligases (N-recognins) 
of the N-end rule pathway (Fig. 1A).  By contrast, 
an otherwise similar expansion of N-end rule in 
prokaryotes involved the appearance of Leu/Phe-
conjugating aminoacyl-tRNA-protein transferases 
such as L/FK,R-transferase (Aat) and LD,E-
transferase (Bpt) (2,12).  While these prokaryotic 
transferases are largely nonsequelogous and 
recognize different N-terminal residues (see 
above), they have in common their conjugation of 
a hydrophobic residue, Leu or Phe, to N-termini 
of their substrates.  This conjugation results in the 
binding of substrates by the ClpS N-recognin. 
A plausible and parsimonious scenario is 
that an N-end rule pathway that targeted 
substrates through bulky hydrophobic but not 
(yet) the other N-terminal residues, emerged in a 
common ancestor of prokaryotes and eukaryotes.  
Being sensitive to protein folding and recognizing 
a “topologically” universal determinant such as a 
substrate’s N-terminal residue, the N-end rule 
pathway is likely to have appeared early, possibly 
coevolving with ribosomes during the emergence 
of translation-endowed organisms.  Subsequent 
expansions of this proteolytic system in 
prokaryotes and eukaryotes kept the rule books of 
N-end rule pathways similar in all organisms 
(presumably owing to a selection for N-end rules 
of certain compositions), but the rule-
implementing machinery has evolved divergently 
in prokaryotes versus eukaryotes.  For example, 
Ub ligases and ubiquitylation emerged (or were 
retained) only in eukaryotes (12,84).  In addition, 
the task of recognizing additional (basic and 
acidic) N-terminal residues in later (more 
elaborate) N-end rule pathways was solved quite 
differently in eukaryotes and prokaryotes, as 
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described above.  Moreover and significantly, the 
evolution of N-end rule’s Ub ligases (N-
recognins) in eukaryotes expanded their 
repertoire of substrate-binding sites beyond the 
N-end rule.  One example is the third site of S. 
cerevisiae UBR1 that recognizes an internal (non-
N-terminal) degron in a transcriptional regulator 
CUP9, and does so in a way that is controlled, 
allosterically, by the occupancy of the other two 
binding sites of UBR1 (see Introduction).  A 
landscape of selective pressures, quasi-neutral 
mutational drifts, and stochastic fixations of 
changes (85) that gave rise to specific differences 
between eukaryotic and prokaryotic N-end rule 
pathways remains to be understood.  This 
problem is made particularly interesting by the 
fact that while the functions of the N-end rule 
pathway in eukaryotes are many and partially 
understood (see Introduction), the functions of 
prokaryotic N-end rule pathways are still 
unknown. 
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FIGURE LEGENDS 
 
FIGURE 1.  The N-end rule pathway in 
the yeast S. cerevisiae.  A, The S .cerevisiae N-
end rule pathway.  N-terminal residues are 
indicated by single-letter abbreviations for 
amino acids. Yellow ovals denote the rest of 
a protein substrate.  Hemin (Fe3+-heme) has 
been found to inhibit the arginylation activity 
of both the S. cerevisiae and mouse ATE1-
encoded Arg-tRNA-protein transferase 
(arginyl-transferase or R-transferase) (4).  At 
least in mammalian cells, hemin also induces 
the proteasome-dependent degradation of R-
transferase (4).  MetAPs, methionine 
aminopeptidases.  “Separase” refers to the 
ESP1-encoded protease that cleaves, in 
particular, the SCC1 subunit of cohesin and 
thereby allows mitosis (86).  The resulting C-
terminal fragment of SCC1 bears a 
destabilizing N-terminal residue (Arg in 
S. cerevisiae) and is degraded by the N-end 
rule pathway, a step that is essential for high 
fidelity of chromosome segregation (43).  
The reactions in a shaded rectangle are a part 
of the N-end rule pathway that is active in 
eukaryotes (e.g., vertebrates) that produce 
nitric oxide (NO) (6), but is also relevant to 
organisms such as S. cerevisiae, which lack 
NO synthases but can produce NO by other 
routes, and in addition can be influenced by 
NO from extracellular sources.  C* denotes 
oxidized Cys, either Cys-sulfinate or Cys-
sulfonate, produced in reactions mediated by 
nitric oxide (NO), oxygen (O2) and their 
derivatives.  Oxidized N-terminal Cys is 
arginylated by ATE1-encoded isoforms of R-
transferase (6,7).  Type-1 and type-2 primary 
destabilizing N-terminal residues (see 
Introduction) are recognized by UBR1, the 
sole N-recognin of S. cerevisiae that 
functions as a holoenzyme containing UBR1 
and the E2 enzyme RAD6.  Through its third 
substrate-binding site, UBR1 recognizes 
internal (non-N-terminal) degrons in 
substrates (denoted by a larger oval) such as 
CUP9, a transcriptional repressor of regulon 
that includes the PTR2 peptide transporter 
(8,39,40).  The addition of hemin to S. 
cerevisiae UBR1 in vitro (in cell extracts) 
was found to inhibit the interaction of UBR1 
(through its third substrate-binding site) with 
CUP9 (4).  This inhibition was selective in 
that hemin did not interfere with the binding 
of primary destabilizing N-terminal residues 
of peptide reporters to the type-1 or type-2 
binding sites of UBR1 (4).  B, Design of a 
genetic screen to isolate UBR1 mutants with 
selectively inactivated type-1 or type-2 substrate-
binding sites.  C, Locations of mutations in S. 
cerevisiae UBR1 that were found to selectively 
inactivate either the type-1 site (UM1 mutations) 
or the type-2 site (UM2 mutations).  The mutant 
residues are in red.  For the names of specific 
UBR1 domains, see refs. (9,29,32), and the main 
text. 
 
FIGURE 2.  Selective inactivation of 
type-1 versus type-2 substrate-binding sites in 
UBR1 mutants.  A, Wild-type UBR1 and its 
mutant alleles were expressed from low-copy 
plasmids in S. cerevisiae JD55 (ubr1Δ) cells that 
also carried a plasmid expressing Arg-βgal (Ub-
Arg-βgal) reporter (see Experimental 
Procedures).  Measurements of βgal activity in 
cell extracts were used to compare the rates of X-
βgal reporter degradation in vivo (9,21).  The 
values shown are the means of duplicate 
measurements of three independent 
transformants.  Standard deviations are indicated 
above the bars.  For the locations of indicated 
mutations in UBR1, see Fig. 1C.  B, Same as in A 
but with cells expressing Leu-βgal (Ub-Leu-
βgal).  C, Pulse-chase assays, using a UPR-type 
construct (21,57) expressing either Met-URA3ha, 
or Arg-URA3ha, or Leu-URA3ha in ubr1Δ cells 
(see Experimental Procedures).  Lane 1, 
molecular mass marker;  their masses, in kDa, are 
indicated on the left.  D, same as in C, but with 
ubr1Δ cells that expressed either wild-type 
UBR1, or its type-1 UBR1D176E-1 mutant, or its 
type-2 UBR1P406S-2 mutant.  The 35S-bands of X-
URA3ha reporters and the DHFRh-Ub reference 
protein are indicated. 
 
FIGURE 3.  In vivo effects of mutants 
in the type-1 or type-2 substrate-binding sites 
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of UBR1.  A, A toxic-peptide (Leu-Eth) 
resistance assay (39,41) (see Experimental 
Procedures) with ubr1Δ S. cerevisiae versus its 
derivatives that expressed type-1 UBR1 mutants 
(Fig. 1C).  B, Same as in A, but the assay was 
carried with type-2 UBR1 mutants, and the result 
with wild-type UBR1 is shown as well (Fig. 1C).  
See the main text for details. 
 
FIGURE 4.  Specific interactions 
between UBR1 and its physiological substrates 
or model ligands.  A, GST-pulldown assays with 
full-length, flag-tagged fUBR1 and immobilized 
Arg-SCC1-GST.  Equal amounts of extract from 
S. cerevisiae that expressed fUBR1 were 
incubated with glutathione-Sepharose beads 
preloaded with Arg-SCC1-GST, in the presence 
of indicated concentrations of either the Arg-Ala 
(RA) or Ala-Arg (AR) dipeptides.  The beads-
associated fUBR1 was eluted from the beads, 
fractionated by SDS-PAGE, and detected by 
immunoblotting with anti-flag antibody (see 
Experimental Procedures).  B, Same as in A but 
with Leu-SCC1-GST and either Leu-Ala (LA) or 
Ala-Leu (AL).  C, The same assay format, with 
Arg-SCC1-GST.  Lane 1, “5%” refers to a 
directly loaded sample of fUBR1-containing 
yeast extract that corresponded to 5% of the 
amount of extract in GST-pulldowns of this 
panel.  Lane 2, Arg-SCC1-GST pulldown assay 
with fUBR1 in the presence of 1 mM AR 
dipeptide (single-letter notations for amino 
acids).  Lanes 3-10, same as lane 2 but with 
either A+R (1 mM free Ala and 1 mM free Arg), 
or RA, or R-OMe (O-methyl ester), or agmatine 
(see the main text), or RD, or RK, or RF, or RL, 
all of them at 1 mM.  D, Same as in C but with 
Leu-SCC1-GST and different dipeptides or 
related compounds, as shown.  Lane 1, Met-
SCC1-GST (instead of Leu-SCC1-GST);  note 
the absence of its interaction with fUBR1, in 
contrast to Leu-SCC1-GST and Arg-SCC1-GST.  
E, Same as in C, but with UBR11-1140f, the N-
terminal “half” of UBR1.  F, Same as in D but 
with UBR11-1140f.  G, Input samples of 
UBR11-1140f and its derivatives.  Lane 1, 
UBR11-1140f.  Lanes 2-7, fUBR11-717, 
UBR1209-1140f, UBR1454-1140f, UBR1710-1140f, 
UBR1866-1140f, and UBR1ha, respectively.  These 
derivatives of UBR1 were overexpressed in S. 
cerevisiae as described for UBR11-1140f.  The 
asterisk denotes a protein crossreacting with anti-
flag antibody.  UBR1ha (lane 7) was employed as 
a (negative) control for antibody specificity.  
“10% input” refers to a directly loaded sample of 
yeast extract that corresponded to 10% of the 
amount of extract in GST-pulldowns of panels H 
and J. H, The X-peptide assay (see Experimental 
Procedures) with UBR11-1140f and its derivatives, 
described in G.  UBR11-1140f and fUBR11-717, but 
not the other UBR1 derivatives of panel G bound 
to immobilized Arg-nsP4pep peptide.  I, Lane 1, 
molecular mass markers.  Lane 2, Coomassie-
stained SDS-PAGE pattern of (overexpressed) 
UBR11-1140f that was purified from yeast extract 
using anti-flag affinity chromatography and used 
for GST-CUP9 pulldowns (see panel K and 
Experimental Procedures). J, same as in H but 
with immobilized Phe-nsP4pep peptide.  K, Lane 
1, 2% input.  Lane 2, GST-CUP9 pulldown with 
UBR11-1140f in S. cerevisiae extract.  Lane 3, same 
as lane 2, but with GST-CUP91-221, a C-
terminally truncated mutant of the 306-residue 
CUP9 that lacks its C-terminal degron (66). Note 
the absence of binding of UBR11-1140f (in yeast 
extract) to GST-CUP91-221, in contrast to its 
binding to full-length GST-CUP91-306.  Lane 4, 
10% input.  Lane 5, same as lane 2 but with 
purified UBR11-1140f, as distinguished from 
UBR11-1140f in yeast extract. Lane 6, same as lane 
5 but with GST-CUP91-221. Note that purified 
UBR11-1140f, in contrast to the same protein in 
yeast extract, binds to both degron-containing 
(lane 5) and degron-lacking CUP9 (lane 6).  Lane 
7, same as lane 5 but with ovalbumin (at 
10 mg/ml) added to UBR11-1140f before GST-
pulldown with full-length GST-CUP9.  Lane 8, 
same as lane 7 but with GST-CUP91-221.  Note 
restoration of the binding specificity of 
UBR11-1140f in the presence of ovalbumin.  Lanes 
9 and 10, same as lanes 5 and 6 but “empty” 
yeast extract was added to purified UBR11-1140f 
before GST-pulldowns with either full-length 
GST-CUP9 (lane 9) or degron-lacking GST-
CUP91-221. 
 
 FIGURE 5.  Measurements of affinity 
between UBR11-1140 and peptides with different 
N-terminal residues using fluorescence 
polarization (FP) assay.  A, Purified UBR11-1140f 
(Fig. 4I) was incubated, at increasing 
concentrations, with either Arg-nsP4pep? 
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peptide (curve 1) or Gly-nsP4pep? peptide 
(curve 2), each of them at 10 nM (C-terminal 
“diamond” in the text and a “star” in the figure 
denote a C-terminal fluorescent tag;  see 
Experimental Procedures).  Note the binding to 
Arg-nsP4pep? (bearing a type-1 destabilizing 
N-terminal residue) and the absence of 
significant binding to Gly-nsP4pep? (bearing a 
stabilizing N-terminal residue).  B, Same as in A 
but with Phe-nsP4pep? versus Gly-nsP4pep? 
(curves 1 and 2, respectively).  C, Competition 
assay, with UBR11-1140f at 1 μM, Arg-nsP4pep? 
at 10 nM, versus increasing concentrations of 
unlabeled Arg-nsP4pep, Phe-nsP4pep, or Gly-
nsP4pep (curves 1-3, respectively).  D, Same as 
in C but with unlabeled dipeptides as 
competitors, at indicated concentrations.  Curves 
1-6, LA, AR, FA, RD, RK, and RA, respectively 
(single-letter abbreviations for amino acids).  E, 
Same as in D, but with an equimolar mixture of 
Arg and Ala (curve 1), Arg-OMe (R-OMe) 
(curve 2), and Arg-Ala (RA) as unlabeled 
competitors.  F, Same as in C, but with 
fluorescent Phe-nsP4pep?, with UBR11-1140f at 
0.7 μM, and the competition with unlabeled Gly-
nsP4pep, Arg-nsP4pep, or Phe-nsP4pep (curves 
1-3, respectively).  G, same as in D but with Phe-
nsP4pep? as a labeled peptide, with UBR11-1140f 
at 0.7 μM, and with unlabeled dipeptides (or their 
derivatives) as competitors.  Curves 1-7, LD, L-
OMe (Leu-OMe), LG, LL, LR, LA, and WA, 
respectively.  H, Same as in G, but with 
Arg-nsP4pep? as a labeled peptide, with 
UBR11-1140f at 0.7 μM, and with unlabeled 
competitors GGGG, RGD, RGDS, RG, or 
RAGESGSGC (single-letter abbreviations for 
amino acids) (curves 1-5, respectively).  The 
RAGES sequence of the latter peptide is identical 
to the N-terminal sequence of the separase-
produced C-terminal fragment of SCC1, a 
physiological N-end rule substrate (see Results 
and Discussion).  I, Same as in H, but with Phe-
nsP4pep? as a labeled peptide, with UBR11-1140f 
at 0.7 μM, and with unlabeled GGGG, FG, FGG, 
FGGF, FA, and Phe-nsP4pep peptide as 
competitors (curves 1-6, respectively). 
 
 FIGURE 6.  Measurements of affinity 
between UBR11-1140 and peptides with different 
N-terminal residues using surface plasmon 
resonance. A, Biacore sensograms (see 
Experimental Procedures) illustrating the binding 
of UBR11-1140f to the immobilized 12-residue 
Arg-nsP4pep peptide, bearing a type-1 primary 
destabilizing N-terminal residue.  RU, resonance 
units.  The curves labeled 1 to 5 correspond to 
the passing of purified UBR11-1140f, at either 
0.188 μM, 0.375 μM, 0.75 μM, 1.5 μM or 3 μM, 
over immobilized Arg-nsP4pep.  B, Same as in A 
but with immobilized Phe-nsP4pep, bearing a 
type-2 primary destabilizing N-terminal residue 
(Fig. 1A).  C, Same as in A but with Gly-nsP4pep 
bearing a stabilizing N-terminal residue (no 
detectable binding to UBR11-1140f at any of its 
tested concentrations).  D and E, Binding 
isotherms (derived from the data in A and B, 
respectively) for Arg-nsP4pep and Phe-nsP4pep 
(see Experimental Procedures). 
 
FIGURE 7.  CUP9 mutants, UBR1-
CUP9 interactions, and effects of 
macromolecular crowding on the specificity of 
interaction between purified proteins.  A, Map 
of the 306-residue CUP9 and its truncation 
mutants.  B, GST-pulldown assays with 
UBR11-1140f and GST fusions to indicated CUP9 
derivatives (see also the legend to Fig. 4, 
Experimental Procedures and the main text).  
Lane 1, “5%” refers to a directly loaded sample 
of UBR11-1140f-containing yeast extract that 
corresponded to 5% of the amount of extract in 
GST-pulldowns of this panel.  Lane 2, GST-
pulldown with UBR11-1140f and GST fusion to 
wild-type CUP9.  Lanes 3-7, same as lane 2 but 
with GST fusions to CUP9 mutants.  Lane 8, 
same as lane 2, but GST lacking the CUP9 
moiety.  The band of UBR11-1140f (retained on 
glutathione-Sepharose beads) is indicated.  C, 
Lane 1, same as lane 1 in B, except that the test 
S. cerevisiae extract contained full-length fUBR1.  
Lanes 2-9, GST-pulldowns with fUBR1 and the 
indicated GST-CUP9 fusions.  As indicated 
above the lanes, all samples except those in lanes 
3 and 5 contained a mixture of Arg-Ala (RA) and 
Leu-Ala (LA) dipeptides, each of them at 1 mM 
(see Experimental Procedures).  Lane 10, same as 
lane 2, but with GST alone.  D, Lane 1, 
molecular mass markers;  a single and double 
asterisks denote, respectively, 220 and 60 kDa.  
Lane 2, Coomassie-stained gel of purified full-
length fUBR1.  E, Lane 1, same as lane 1 in C, 
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but 2% of total fUBR1 in the assay.  Lanes 2, 3, 
same as lanes 3, 2 (respectively) in C, but an 
independent experiment.  Lane 4, same as lane 1, 
but with purified fUBR1.  Lanes 5, 6, same as 
lanes 2, 3 but with purified fUBR1 to which was 
added an “empty” (lacking fUBR1) S. cerevisiae 
extract.  Note that purified fUBR1 assayed in the 
presence of “added-back” yeast extract exhibited 
specific (dipeptides-dependent) binding to GST-
CUP9 (lanes 5, 6), indistinguishably from fUBR1 
that had not been initially purified (lanes 2, 3).  
F, Lanes 1-4, same as lanes 1-4 in E but an 
independent experiment.  Lane 4, same as lane 1, 
but 10% of the input sample of the purified 
fUBR1 (see lane 2 in D).  Lanes 5, 6, same as 
lanes 2,3 but with purified fUBR1.  Note the lack 
of dependence of UBR1-CUP9 interaction on the 
presence of cognate dipeptides.  Lanes 7, 8, same 
as lanes 5, 6 but GST-pulldowns were carried out 
in the presence of added ovalbumin, at 10 mg/ml.  
G, Lanes 1-3, same as lanes 1-3 in E or F, but an 
independent experiment.  Lane 4, same as lane 4 
in F, but an independent experiment.  Lanes 5, 6, 
same as lanes 7, 8 in F, but with ovalbumin at 50 
mg/ml.  Lanes 7, 8, same as lanes 5, 6, but with 
purified EF1α added to the assay (to 1.2 mg/ml), 
instead of ovalbumin.  Lanes 9, 10, same as lanes 
7, 8, but in the absence of added EF1α.  H, 
Coomassie-stained gel of purified EF1α (see 
Experimental Procedures).  I, Lane 1, same as 
lane in F, but an independent experiment.  Lanes 
2, 3, same as lanes 2, 3 in E or F, but with GST-
CUP9L294P, a previously characterized missense 
mutant of CUP9 (in the region of its degron) that 
did not bind to UBR1 and was metabolically 
stabilized in vivo (8).  Note the absence of 
binding of fUBR1 (in the extract) to GST-
CUP9L294P, irrespective the absence or presence 
of dipeptides.  Lane 4, same as lane 4 in F, but an 
independent experiment.  Lanes 5, 6, same as 
lanes 2, 3 but with purified fUBR1.  Note that 
purified fUBR1 binds to degron-impaired GST-
CUP9L294P, and does so irrespective of the 
presence or absence of dipeptides.  J, Lane 1, 
same as lanes 4 in F or I, but an independent 
experiment.  Lanes 2, 3, same as lanes 5, 6 in F, 
but in the presence of ovalbumin (at 50 mg/ml).  
Lanes 4, 5, same as lanes 2, 3 but with GST-
CUP9L294P, instead of “wild-type” GST-CUP9.  
K, Lane 1, same as lane 1 in F, but an 
independent experiment.  Lane 2, 3, same as 
lanes 2, 3 in F and G, but with GST-CUP9222-306, 
an N-terminally truncated CUP9.  Note the 
retention of specific (dipeptides-modulated) 
binding of this CUP9 derivative to fUBR1.  Lane 
4, same as lane 4 in F, but an independent 
experiment.  Lanes 5, 6, same as lanes 2, 3 but 
with purified fUBR1.  Lanes 7, 8, same as lanes 
5, 6, but with added ovalbumin (ov), at 50 
mg/ml.  Note the restoration of specific binding.  
L, An alternative UBR1-CUP9 binding assay in 
which the interactions were probed using 
coimmunoprecipitation of fUBR1 and pyCUP9, a 
GST-lacking, full-length CUP9 bearing the N-
terminal “polyoma”(py) epitope tag (see 
Experimental Procedures).  Flag-tagged fUBR1 
in the yeast extract was incubated with beads-
immobilized anti-flag antibody, followed by 
isolation of fUBR1-bearing beads by 
centrifugation, washes with binding buffer and 
incubation with either purified pyCUP9 alone 
(lanes 2, 3, upper panel) or in the presence of 
(added) UBR1-lacking yeast extract (lanes 4-7).  
The incubations were carried out in either the 
absence (lanes 2, 4, 6) or the presence of Arg-Ala 
(RA) and Leu-Ala (LA) dipeptides, each of them 
at 1 mM.  The beads containing immobilized 
fUBR1 were pelleted by centrifugation, washed, 
and the relative amounts of retained pyCUP9 were 
then determined by SDS-PAGE and 
immunoblotting with anti-py antibody (see 
Experimental Procedures).  The upper panel 
shows the amounts of pyCUP9 that were bound to 
fUBR1 in the absence of added yeast extract 
(lanes 2, 3) or in the presence of extract.  Lane 1 
shows the amount of pyCUP9 that corresponds to 
10% of its input in each of the binding assays.  
The lower panel is the result of SDS-PAGE and 
immunoblotting (with anti-flag antibody) of 
fUBR1 that was eluted from anti-flag beads by 
the flag peptide, to verify the approximate 
equality of “input” levels of fUBR1 in each assay.  
Note that in the absence of added (UBR1-
lacking) yeast extract, the interaction between 
fUBR1 and pyCUP9 was nonspecific, in that it 
was independent of the absence or presence of 
cognate dipeptides (lanes 2, 3;  compare with 
lanes 4-7).  Lanes 6, 7, same as lanes 4, 5, but the 
input pyCUP9 was 2-fold higher. 
 
 FIGURE 8.  Synergistic Effects of 
Type-1/2 Dipeptides in a UBR1-Dependent 
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Ubiquitylation System.  Reactions consisting of 
purified S. cerevisiae Ub, purified UBA1 (E1, 
Ub-activating enzyme), RAD6 (the N-end rule 
pathway’s E2, Ub-conjugating enzyme), UBR1 
(the N-end rule pathway’s E3 Ub ligase), 35S-
labeled, purified CUP9, and ATP were 
supplemented with pairs of purified dipeptides, at 
indicated concentrations.  The pairs of added 
dipeptides were Arg-Ala plus Ala-Leu (RA+AL), 
or Leu-Ala plus Ala-Arg (LA+AR), or Arg-Ala 
plus Leu-Ala (RA+LA), or Ala-Arg plus Ala-Leu 
(AR+AL).  The reactions were incubated at 30°C 
for 10 min, followed by SDS-10% PAGE and 
autoradiography (see Experimental Procedures).  
Unmodified CUP9 and CUP9-linked poly-Ub 
chains are indicated on the left.  Asterisk on the 
right denotes a protein present in the initial CUP9 
sample, possibly an SDS-resistant dimer of 
CUP9.  Lane 1, purified CUP9 (input).  Lanes 2-
10, same as in B, but a set of independently 
performed reactions, with different 
concentrations of added dipeptide pairs.  Note a 
synergistic enhancement of CUP9 
polyubiquitylation in the presence of RA+LA 
(lane 9). 
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